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The malaria parasite Plasmodium utilizes specialized proteins for adherence to cellular 
receptors in its mosquito vector and human host. Adherence is critical for parasite development, 
host cell traversal and invasion, and protection from vector and host immune mechanisms. These 
vital roles have identified several adhesins as vaccine candidates. A deficiency in current 
adhesin-based vaccines is induction of antibodies targeting non-conserved, non-functional, and 
decoy epitopes due to the use of full length proteins or binding domains. To alleviate the 
elicitation of non-inhibitory antibodies, conserved functional regions of proteins must be 
identified and exploited. Structural biology provides the tools necessary to achieve this goal, and 
has succeeded in defining biologically functional receptor binding and oligomerization interfaces 
for a number of promising malaria vaccine candidates.  
A critical step in the Plasmodium life cycle is adhesion to and invasion of erythrocytes by the 
merozoite during blood stage growth. The invasion process requires the formation of a tight 
junction between parasite adhesive proteins and red cell receptors. Formation of this junction 
allows the merozoite to engage and enter the red cell to form the parasitophorous vacuole. The 
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Erythrocyte-binding-like (EBL) family of cellular adhesion proteins is implicated in the 
formation of this essential tight junction.  
Receptor binding by the EBL family of invasion ligands has been localized to a specific 
portion of each EBL protein designated Region II (RII). This region is composed of the Duffy-
binding-like (DBL) domain, unique to Plasmodium species. The two Plasmodium species 
responsible for the majority of malaria disease in humans are P. falciparum and P. vivax. There 
are four identified EBL members in P. falciparum that contain two tandem DBL domains in RII. 
This organization contrasts the single DBL domain in RII of the only characterized EBL member 
of P. vivax, Duffy-binding Protein (PvDBP). Using a combination of structural, biophysical, and 
cellular interaction methods we examined the binding mode for these two Plasmodium EBL 
family members to define the molecular and mechanistic basis of unique red cell invasion routes.  
Specifically, we sought to enhance our understanding of the molecular and mechanistic 
details of invasion by Plasmodium EBL ligands with the ultimate goal of identifying novel 
targets for rational vaccination efforts. We examined receptor interactions of a P. falciparum 
EBL member, Erythrocyte-binding-antigen 140 (PfEBA-140) and P. vivax DBP to provide 
insight into invasion by both species of parasite. Our work identified unique interfaces on the 
DBL domain that provide specific recognition of each ligand’s unique red blood cell receptor. 
Additionally, studies examining oligomeric state identified distinct mechanistic parameters for 
the two EBL ligands, and contrasted with the mechanism observed for another P. falciparum 
member, PfEBA-175.   
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Chapter 1 
Introduction 
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Preface 
The thesis introduction was written and figures were prepared by me with comments from 
Niraj H. Tolia. A portion of this chapter was published as a review: [Malpede, B.M. and Tolia, 
N.H. (2014) Malaria Adhesins: Structure and Function. Cellular Microbiology. DOI: 
10.1111/cmi.12276]. 
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1.1 Malaria disease and Plasmodium species 
Malaria eradication efforts have reduced the burden of this devastating parasitic disease, 
however, 3.2 billion people are still at risk for infection, and approximately 198 million cases of 
malaria occur annually and result in an estimated 584,000 deaths (WHO World Malaria Report 
2014). The disease disproportionately affects the sub-Saharan region of Africa, and children 
under the age of 5 years account for 78% of all mortality (WHO World Malaria Report 2014).  
The disease is the result of infection with one of five species of Plasmodium, a genus of 
protozoan parasites. These parasites engage in a complex life cycle involving growth in a vector 
of specific species of anopheles mosquito as well as the human host. Human infection is initiated 
during the blood meal of the female anopheles mosquito, after which the parasite traverses 
through the human dermis, making its way to the liver to replicate until merozoites are released 
into the blood. Merozoites travelling the bloodstream then invade and develop within red blood 
cells (RBCs). This expands the merozoite population and also allows for the development and 
release of gametes for vector uptake and initiation of a new transmission cycle. The clinical 
symptoms and death associated with malaria are the result of intricate host-pathogen interactions 
during blood stage growth and are dependent on the parasite attaching to and invading RBCs 
(Cowman et al., 2006, Cowman et al., 2012, Miller et al., 2013). Cellular adhesion is essential 
during growth in both the mosquito vector and human host, and is a multifaceted physical ability 
that affords the parasite access to unique cellular niches, aids in parasite reproduction, and 
provides protection from host immunity. 
Specifically, adhesion of Plasmodium malaria parasites to host cells is critical in mediating 
traversal through cellular barriers, cellular invasion, and protection from host clearance. To 
traverse host cells, the parasite disrupts the host membrane, glides through the cytosol, and exits 
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the cell (Mota et al., 2001). This movement contrasts cellular invasion, during which the parasite 
engages the host cell and invaginates the membrane to form the parasitophorous vacuole, where 
the parasite resides as it develops internally (Baum et al., 2008, Cowman et al., 2012). Adhesins 
also mediate rosetting and cytoadherence of infected erythrocytes within the human host, 
effectively providing protection from immune clearance by the spleen (Rowe et al., 2009).  
 5 
 
1.2 The structure and function of Plasmodium adhesins 
Proteins that provide adhesive and invasion functions contain defined domains and are 
organized into families based on domain similarity. Atomic resolution crystal structures of 
adhesins, alone and in complex with host receptors, have delineated protein folds and structurally 
conserved segments. More importantly, structures have identified receptor binding interfaces, 
multimeric contacts, and mechanisms of receptor binding. Evaluation of protein ultrastructure 
and oligomeric state complemented crystallographic studies by illuminating an overall view of 
protein shape, flexibility, and multimeric assembly in solution. 
Described below is our current knowledge of how protein structures of malaria adhesins 
provide wide ranging cell adherence functions with defined roles in the parasite life cycle. 
Families of proteins that are proposed to coat the parasite at multiple life cycle stages are 
discussed first, followed by the multiple adhesive roles of the sporozoite surface coat protein. 
Proteins the parasite utilizes to invade RBCs are then detailed. The role of adhesion throughout 
parasite invagination of the host membrane during cellular invasion is discussed, along with 
proteins that provide a link between extracellular receptors and the parasite’s internal actin 
motor. In addition, I provide a discussion of adhesins exported to the surface of infected RBCs 
that bind numerous receptors to provide rosetting and cytoadherence capabilities. I link the 
common structural features that serve similar adhesive purposes (Figure 1), and highlight 
multimeric assembly necessary for adhesion.  
Proteins functioning as a parasite surface coat 
The mosquito blood meal initiates the growth of the parasite in its vector, as gametes enter 
the proper environment for fertilization. Surface coat adhesins are immediately required, and 
gametes utilize members of the conserved Apicomplexan 6-cysteine family for recognition and 
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attachment during fertilization (van Dijk et al., 2001, van Dijk et al., 2010). 6-cysteine family 
members are also expressed on the surface of sporozoites and merozoites and are likely 
redundant adhesins at cellular invasion interfaces (Ishino et al., 2005, Sanders et al., 2005) . 
Members in this family contain a varied number of s48/45 domains, a predominantly beta-sheet 
fold (Fig. 2A) (Arredondo et al., 2012, Tonkin et al., 2013).  The crystal structure of Pf12, a 
merozoite protein, illuminated only minor contacts between the tandem s48/45 domains, and 
showed that the domain linker lacks conformationally restrictive residues (Tonkin et al., 2013). 
This suggests that movement between two tandem s48/45 domains is possible, and thus that the 
link between the two domains is flexible. Furthermore, Pf12 forms heterodimers with another 6-
cysteine member, Pf41, suggesting that 6-cysteine family proteins may function as pairs 
(Taechalertpaisarn et al., 2012).  
The domain fold of 6-cysteine family members contrasts the fold of the surface coat proteins 
on the fertilized zygote and ookinete within the mosquito midgut. After fertilization, zygotes are 
capable of adhering to one another through tubule extensions coated in the protein p25, an 
adhesin that contains four tandem evolutionarily conserved epidermal growth factor-like (EGF) 
domains (Fig. 2B) (Saxena et al., 2006, Rupp et al., 2011). p25 and its homolog, p28, are 
subsequently expressed on the surface of the motile ookinete, the parasite form that results from 
the developing zygote (Saxena et al., 2007). As ookinete surface proteins, p25 and p28 are 
thought to provide protection from mosquito proteolytic defense mechanisms and to facilitate 
adhesion to the midgut membrane (Tomas et al., 2001, Saxena et al., 2007). Adherence likely 
depends on p25/p28 binding to laminin, which constitutes a large portion of the midgut 
epithelium (Vlachou et al., 2001). Knocking out both p25 and p28 is required to severely limit 
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midgut crossing, suggesting both proteins are critical for adhesion and are functionally redundant 
(Tomas et al., 2001). 
Crystallization of P. vivax p25 identified extensive contacts between monomers in the crystal 
lattice (Fig. 2B) (Saxena et al., 2006). Contacts between p25 monomers form a “triangular 
prism” that may link the proteins on the ookinete surface to form a specific coat structure (Tomas 
et al., 2001, Saxena et al., 2006, Saxena et al., 2007). It is important to note that the way in 
which a protein packs into a crystal can result in artificial contacts that may not be functional in 
vivo. Crystal packing interfaces and oligomeric states should be assessed in solution to support 
inferences made from crystal structures. The intermolecular contact residues are conserved 
among p25 orthologs and monomers can self-interact in solution, supporting a physiological role 
for multimerization (Siden-Kiamos et al., 2000, Saxena et al., 2006, Saxena et al., 2007). 
Together, these studies suggest that multimeric complexes of p25 and/or p28 form a protective 
coat and initiate and maintain interactions with the midgut cell wall (Tomas et al., 2001). 
In contrast to the surface coat of the ookinete, the sporozoite does not express any 
characterized EGF containing proteins, but instead utilizes circumsporozoite protein (CSP), 
discussed below. However, EGF-like domains are used again on the surface of the merozoite 
after release from the human liver. The merozoite surface protein family (MSP), of which MSP1 
is the most abundant, coats the merozoite and provides adhesive functions. MSP1 is a 185–215 
kDa protein that undergoes extensive proteolytic processing resulting in multiple subunits non-
covalently linked to the C-terminal portion designated MSP1-19 (Fig. 2C). At the point of RBC 
invasion, all subunits of MSP1 are released except for MSP1-19 (Holder et al., 1984, Kauth et 
al., 2003). MSP1-19 contains two tandem EGF domains that are compact and rigid, and is linked 
to the membrane by a GPI anchor (Fig. 2C) (Chitarra et al., 1999, Morgan et al., 1999). . The 
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structure of MSP1-19 in complex with an antibody that effectively coats the merozoite surface 
identified a region of MSP1-19 that is exposed on the merozoite (Pizarro et al., 2003). This 
region may contact Band 3, the erythrocyte receptor for MSP1 (Goel et al., 2003).  
The CSP surface coat on sporozoites 
CSP comprises the surface coat of the sporozoite during its journey through the mosquito 
salivary glands to invasion of human hepatocytes (Kappe et al., 2004). CSP possesses a distinct 
domain architecture: an N-terminal domain, a sequence designated Region I, a stretch of tetra-
amino acid repeats, a C-terminus comprised of two Regions designated II and III, and an 
evolutionarily conserved thrombospondin type-I repeat (TSR) domain. A GPI anchor links CSP 
to the membrane (Wang et al., 2005).  
The domains of CSP function in two distinct steps of the sporozoite’s life cycle. Initially, the 
CSP N-terminal domain/Region I binds heparan sulfate on the mosquito salivary glands 
(Sidjanski et al., 1997, Sinnis et al., 2007, Ghosh et al., 2009b, Armistead et al., 2011). Upon 
initiation of the mosquito blood meal, sporozoites are injected from the salivary glands into the 
human and migrate to the liver. Within the liver, the second step of CSP host cell recognition 
depends on proteolytic removal of the N-terminal domain and timed exposure of the C-terminal 
TSR domain (Coppi et al., 2005, Coppi et al., 2011). This exposure is correlated with 
recognition of increased sulfation of heparan sulfate proteoglycans on hepatocytes (Coppi et al., 
2007, Coppi et al., 2011). Mutant sporozoites that constitutively express the cleaved version of 
CSP, exposing the TSR domain, continually migrate within the dermis and do not reach the liver. 
This suggests that the N-terminal domain prevents the CSP C-terminal region from binding 
improper receptors in the dermis, allowing the sporozoite to properly target the liver (Coppi et 
al., 2011). Retaining the N-terminus prior to hepatocyte recognition also shields the functional 
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C-terminal binding region from antibody recognition, representing an in vivo structural 
mechanism for protection of critical binding domains (Coppi et al., 2011).  
Ultrastructural analysis suggests that CSP maintains a flexible rod-like structure (Plassmeyer 
et al., 2009). Small percentages of CSP appear to form dimers and oligomers in solution, 
suggesting that intermolecular contacts may function in sporozoite coat formation (Plassmeyer et 
al., 2009). Extensive interdomain contacts are formed between the TSR domain and Region III 
(Fig. 2D) (Doud et al., 2012). However, the TSR and Region III construct is monomeric in 
solution. Thus, CSP oligomerization may depend on the N-terminal domain or Region I and/or 
Region II, and internal repeat regions have been proposed to interact to form a protective coat for 
the parasite (Godson et al., 1983).  
Surface proteins that adhere to cellular receptors during invasion 
After release from the liver into the bloodstream, the merozoite recognizes RBCs and must 
form a tight link with the host cell membrane. Two distinct protein families are involved at this 
stage: the Erythrocyte-binding-like (EBL) and the Reticulocyte-binding-like Protein Homologue 
(RH). Members of both families engage specific RBC receptors for invasion (Sim et al., 1990, 
Adams et al., 1992).  
The EBL family contains a conserved domain architecture (Adams et al., 1992). Receptor 
binding requires essential adhesive domains unique to Plasmodium termed Duffy Binding-like 
(DBL) found in Region II (RII) of EBL proteins. P. falciparum contains multiple EBL family 
members (PfEBA-175, PfEBA-140, PfEBL-1 and PfEBA-181), each containing two tandem 
DBL domains. In contrast, P. vivax is thought to be limited to a sole EBL member, Duffy 
Binding Protein (PvDBP), which contains a single DBL domain. However, sequencing of field 
isolates of P. vivax have revealed certain isolates carry a duplication of the PvDBP gene (Menard 
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et al., 2013), and others carry a novel EBL ligand that also has a single DBL domain (Hester et 
al., 2013). The DBL domains have a characteristic boomerang shape stabilized by extensive 
disulfide bridging (Tolia et al., 2005, Singh et al., 2006, Higgins, 2008, Khunrae et al., 2009, 
Batchelor et al., 2011, Juillerat et al., 2011, Lin et al., 2012, Vigan-Womas et al., 2012, Malpede 
et al., 2013). In addition to Region II, EBL proteins contain a segment of uncharacterized 
structure (Regions III-V), a structured C-terminal cysteine rich domain (Region VI), a 
transmembrane domain, and a cytoplasmic region (Adams et al., 1992, Withers-Martinez et al., 
2008). 
PfEBA-175-RII contains two tandem DBL domains that bind Glycophorin A in a sialic acid 
dependent manner (Camus et al., 1985, Sim et al., 1990, Klotz et al., 1992, Orlandi et al., 1992, 
Sim et al., 1994). The crystal structure of PfEBA-175-RII in complex with a sialic acid 
containing glycan revealed the receptor-binding pockets are formed at the dimer interface of 
PfEBA-175-RII (Fig. 2E) (Tolia et al., 2005). This suggests a dimer of PfEBA-175 assembles 
around dimeric Glycophorin A during invasion. Multimeric assembly of PfEBA-175 enhances 
binding to Glycophorin A and is augmented by regions outside of RII (Salinas et al., 2013, 
Wanaguru et al., 2013). 
The P. vivax EBL member, PvDBP-RII, shares similar molecular structures and functional 
characteristics with PfEBA-175-RII (Tolia et al., 2005, Batchelor et al., 2011, Batchelor et al., 
2013, Wanaguru et al., 2013). PvDBP-RII is monomeric in the absence of its receptor, the Duffy 
Antigen Receptor for Chemokines (DARC), and dimerization of PvDBP-RII is driven by 
receptor binding (Fig. 2F) (Batchelor et al., 2011). Crystal structures of PvDBP-RII in complex 
with the ectodomain of DARC, and complementary solution studies, demonstrated formation of 
two distinct complexes: a heterotrimer of two PvDBP-RII and one DARC, and a heterotetramer 
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of two PvDBP-RII and two DARCs (Batchelor et al., 2013). These complexes are intermediates 
in a multi-step binding mechanism. In both structures, DARC is sandwiched by two PvDBP-RII 
molecules facilitating receptor-induced dimerization, suggesting a conserved binding mechanism 
between two EBL ligands despite distinct dimeric architectures (Figure 2E and 2F). However, 
the receptor binding sites and dimer interfaces lie on distinct faces of the DBL domains. 
Crystal structures of PfEBA-140 Region II also identified receptor binding regions (Fig. 2G) 
(Lin et al., 2012, Malpede et al., 2013). PfEBA-140-RII is monomeric in the absence of its 
receptor Glycophorin C (Lobo et al., 2003, Lin et al., 2012, Malpede et al., 2013) and further 
studies of receptor-bound PfEBA-140 and other EBL ligands are necessary to determine if 
multimeric assembly occurs upon receptor binding. The receptor binding pockets in PfEBA-140 
are located in a distinct region of the DBL fold compared to the pockets used by either PfEBA-
175-RII or PvDBP-RII. This suggests that the DBL fold can create multiple binding pockets to 
bind a wide variety of receptors. PfEBA-140 also exhibits polymorphisms that affect receptor-
specificity and/or binding affinity (Mayer et al., 2002, Maier et al., 2009), and a polymorphism 
that maps to one receptor-binding pocket suggests a structural basis for altered specificity 
(Malpede et al., 2013). Additional merozoite surface proteins containing the DBL domain bind 
RBCs and maintain the conserved DBL architecture (Hodder et al., 2012). The specific role of 
these DBL containing proteins during invasion is not completely understood.  
EBL ligands function primarily in the blood stage, but one unique member, designated 
Apical membrane antigen/erythrocyte binding like (MAEBL), enables sporozoite entry into the 
mosquito salivary glands (Blair et al., 2002, Kariu et al., 2002, Fu et al., 2005). Sporozoites 
lacking MAEBL cannot attach to the salivary glands, but retain normal motility, supporting a 
specific role in attachment to host cells (Kariu et al., 2002). Unlike most EBL proteins that 
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contain DBL domains, the tandem adhesive domains in MAEBL contain homology to domains 
observed in Apical Membrane Antigen -1 (AMA-1), described below. MAEBL may be involved 
in a similar function at the moving junction as AMA-1, and may incorporate functional elements 
of AMA-1 and the EBL family. 
Recent studies have illuminated the structure of the RH family of invasion ligands, and have 
focused on RH5 due to its proposed essentiality (Crosnier et al., 2011). Initial efforts illuminated 
a low resolution surface envelope of the RBC binding element from a RH family member (P. 
yoelli235) and suggested that this segment may resemble Region II of the EBL family (Gruber et 
al., 2011). However, the recent crystal structure of RH5 in complex with its receptor, Basigin, 
exhibited a novel invasion protein fold consisting helical bundles presenting receptor interaction 
interfaces near the N-terminus (Chen et al., 2014, Wright et al., 2014). Structures of RH5 in 
complex with inhibitory antibodies illuminated targeted epitopes localized to the receptor 
binding interface, similar to the results observed for the antibody response to EBL ligands 
(Batchelor et al., 2011, Batchelor et al., 2013, Chen et al., 2013). 
Adhesion during membrane invagination to form the parasitophorous vacuole 
In addition to forming a connection with the host cell membrane, the parasite must maintain 
this link during membrane invagination and engulfment into the parasitophorous vacuole, where 
it will develop internally. This membrane invagination requires the formation of the moving 
junction, a ring-shaped link between parasite and host membranes that begins at the apical end of 
the merozoite and migrates to the posterior end as the parasite invades. AMA-1 is a unique 
adhesin that is released during invasion, and is observed at the moving junction (Triglia et al., 
2000, Lamarque et al., 2011). AMA-1 is expressed on sporozoites, and antibodies targeting this 
adhesin inhibit hepatocyte invasion, suggesting a functional role in the liver stage (Silvie et al., 
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2004). Initial attempts to knockout AMA-1 were unsuccessful, however, more recent studies 
suggest AMA-1 is dispensable for blood stage growth (Bargieri et al., 2013). 
AMA-1 is a type I integral membrane protein, and the extracellular portion is composed of 
three Domains (I, II, and III) defined by disulfide bridging (Hodder et al., 1996). The 
cytoplasmic region is conserved amongst Plasmodium species, and contains two C-terminal 
tyrosines that are proposed to function in signaling through phosphorylation, potentially 
providing communication with downstream effectors (Remarque et al., 2008). Domains I and II 
of AMA-1 adopt the evolutionarily conserved PAN domain fold, which mediates diverse 
protein-protein and protein-carbohydrate interactions (Fig. 2H) (Tordai et al., 1999, Bai et al., 
2005, Pizarro et al., 2005). Domain III adopts a novel fold (Pizarro et al., 2005).  
AMA-1 is not known to engage a host cell receptor. Instead, it binds the parasite expressed 
RON2, which is secreted from the merozoite rhoptries into the RBC membrane during invasion 
(Cao et al., 2009, Srinivasan et al., 2011). Crystallization with a peptide comprising the minimal 
RON2 binding domain clarified a specific hydrophobic groove of Domain I that engages the 
receptor (Vulliez-Le Normand et al., 2012). Displacement of a loop in Domain II is required for 
RON2 binding to AMA-1, and this loop may function to protect the binding site from host 
immunity until RON2 is available (Vulliez-Le Normand et al., 2012). AMA-1 binds the RON2 
peptide with nanomolar affinity, and this interaction is strengthened by high local concentration 
and clustering of several independent AMA-1/RON2 interactions to facilitate moving junction 
formation (Vulliez-Le Normand et al., 2012). This clustering of interactions provides necessary 
avidity to maintain the parasite’s link to the host membrane as the parasite propels itself into a 
host cell.  
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The link between host cell receptors and the parasite's actin motor 
The formation of the moving junction is accompanied by parasite movement that links an 
external host cellular receptor with the parasite's internal actin motor (Kappe et al., 1999, Baum 
et al., 2006). The thrombospondin related anonymous protein (TRAP) family provides this 
connection. TRAP family members contain a combination of adhesive evolutionarily conserved 
Von-Willebrand Factor Type A (VWA) and TSR domains. The cytoplasmic portion of TRAP 
members links to the actin motor through aldolase providing movement (Fig. 2I) (Buscaglia et 
al., 2003, Kappe et al., 2004, Bosch et al., 2007). Sporozoites deficient in the hallmark member 
of this family, TRAP, are capable of adhering to host cells, suggesting that TRAP function is 
required for invasion but not attachment (Sultan et al., 1997). 
The VWA and TSR domains of PfTRAP and PvTRAP have been captured in various 
conformations by x-ray crystallography (Song et al., 2012). The VWA domains appear rigid but 
can adopt open and closed conformations with the closed conformation correlated with divalent 
cation binding. In contrast, the TSR domains are highly flexible, evidenced by complete disorder 
in PfTRAP and two distinct orientations in the open conformations of PvTRAP. This led the 
authors to suggest that TSR domains become structured upon receptor binding and the observed 
conformational changes may be necessary to initiate motility into the cell (Song et al., 2012).  
An individual TRAP member is proposed to function at different stages of the parasite's life 
cycle (Baum et al., 2006). Movement through the mosquito midgut cellular barrier is the 
function of CTRP binding to laminin, as genetic deletion of CTRP severely disrupts this ability 
(Yuda et al., 1999a, Yuda et al., 1999b, Mahairaki et al., 2005). TRAP, present on the 
sporozoite, is required for movement into the mosquito salivary glands via binding to Saglin and 
also mediates hepatocyte invasion (Sultan et al., 1997, Wengelnik et al., 1999, Kappe et al., 
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2004, Ghosh et al., 2009a). The parasite must also actively invade RBCs during blood stage 
growth, and MTRAP provides motor function at this juncture. The receptor for MTRAP has been 
defined as Semaphorin-7A, and the two appear to bind in a 2:2 complex (Bartholdson et al., 
2012).  Ultrastructural analysis demonstrates that MTRAP maintains an extended conformation 
that may provide flexibility that facilitates the active movement of the parasite into a host cell 
(Uchime et al., 2012). This flexible form may represent the overall shape of the TRAP family.  
Adhesive proteins exported to the infected RBC surface 
Within the RBC, the parasite actively exports variant surface antigens to the RBC membrane 
(Leech et al., 1984, Baruch et al., 1995, Smith et al., 1995, Su et al., 1995). The var gene family 
encodes erythrocyte membrane protein 1 (PfEMP1), which provides critical adhesive properties 
that provide protection from immune function (Baruch et al., 1995, Smith et al., 1995). The var 
gene family in P. falciparum contains approximately 60 unique variants in each haploid parasite 
genome, of which one variant is predominantly expressed at a given time (Chen et al., 1998, 
Scherf et al., 1998, Gardner et al., 2002). Each member contains an N-terminal domain along 
with a varied combination of two major Plasmodium specific adhesion domains: the DBL fold, 
and a cysteine rich interdomain region (CIDR) that is also highly alpha helical (Fig. 2J) (Smith et 
al., 2000, Heddini et al., 2001, Higgins, 2008, Klein et al., 2008, Khunrae et al., 2009). Similar 
to the DBL domains of merozoite adhesins, the PfEMP1 DBL domains appear to have a wide 
receptor range. The CIDR domains are also involved in receptor recognition, further increasing 
the receptor repertoire engaged by PfEMP-1.  
Solution structural analysis by Small-angle X-ray Scattering (SAXS) of a recombinant full 
length extracellular region of one PfEMP1 variant, IT4VAR13, showed a flexible, extended 
molecule (Brown et al., 2013). In contrast, examination of a second PfEMP1 variant, 
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VAR2CSA, showed that the DBL-CIDR domains assemble into higher order structures that may 
involve domain-domain interactions (Srivastava et al., 2010). The full length extracellular region 
of VAR2CSA was required for highest affinity receptor binding, supporting a crucial role for 
interdomain interactions (Srivastava et al., 2010). Crystal structures of constructs containing the 
tandem N-terminus, DBL, and adjacent CIDR domain displayed extensive contacts between the 
individual elements of the PfEMP1 architecture (Juillerat et al., 2011, Vigan-Womas et al., 
2012). The functional role for inter-domain contact is not clear, however, the domain-domain 
contacts represent a view that contrasts the previously invoked model of “beads on a string,” in 
which all PfEMP1 domains are flexible and capable of binding individual, unique receptors. 
Although individual domains are proposed to bind unique receptors, the role of each domain as a 
piece of the whole PfEMP1 protein is not fully understood.  
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1.3 Targeting adhesion proteins in vaccines 
Exposure on the parasite surface marks Plasmodium adhesins as prime targets for host 
immunity and vaccines. The focus of current anti-malaria vaccines on full length adhesins or 
complete binding domains grants the immune system with access to decoy and non-inhibitory 
epitopes (Chen et al., 2013), diminishing the production of inhibitory antibodies. Limiting or 
eliminating access to decoy and non-functional epitopes is critical towards developing rapid and 
effective immunity. Structural work has successfully defined conserved receptor binding sites 
and multimeric interfaces that can be specifically targeted to focus an antibody response. 
Functional interfaces have been defined by crystallizing the adhesin with receptors, and with 
characterized inhibitory antibodies. Techniques that focus the immune response to target specific 
epitopes are currently in development. Specific epitope targeting can be achieved by mutating 
immune-dominant non-inhibitory epitopes and by shrouding non-inhibitory epitopes with 
glycosylation (Ntumngia et al., 2012, Sampath et al., 2013). Similar approaches have effectively 
defined broadly-neutralizing epitopes to viral antigens, supporting the efficacy of these 
techniques (Corti et al., 2013). Continued structural effort to identify critical and conserved 
contacts between parasite and host proteins provides an excellent opportunity in the development 
of vaccines that elicit strain-transcendent, highly inhibitory antibodies to malaria parasites. 
RBC invasion ligands as targets for vaccination 
The process of merozoite recognition and invasion of RBCs occurs in distinct stages 
(Cowman et al., 2006, Cowman et al., 2012). Initial low affinity recognition of the RBC is 
followed by reorientation of the merozoite with its apical tip facing the RBC membrane. This 
orientation initiates release of  micronemes and rhoptries, organelles containing proteins that 
form an essential tight junction between parasite and host cell membranes and allow the 
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merozoite to insert itself into the cell, forming a parasitophorous vacuole for internal growth and 
development (Aikawa et al., 1978, Bannister et al., 1990, Weiss et al., 2015).Targeting 
interactions during recognition and insertion into the RBC provides an excellent intervention 
strategy, as it prevents the parasite from expanding its population and limits the formation of 
gametes, thus reducing or eliminating symptoms and transmission to new hosts (Sheehy et al., 
2013). The following thesis work examines the atomic and molecular basis of invasion for two 
unique ligands of the EBL family, PfEBA-140 and PvDBP, focusing on defining receptor 
interaction interfaces, determinants of receptor specificity, and biophysical binding mechanisms. 
The ultimate objective of this work is to define functional elements of DBL domains for rational 
targeting in a blood-stage malaria vaccine.   
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1.4 Figures 
 
Figure 1. Domain architectures of adhesive proteins functioning at different parasite life stages. 
For families with a varied number and/or organization of adhesive domains, the most well 
characterized member of the family is shown. The domains are color coded and identified in the 
two boxes within the figure. 
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Figure 2. Crystal structures define adhesive folds used by the malaria parasite.  
A. The structure of Pf12, representing the s48/45 domain. Members of the 6-cys family exhibit a 
range in their number of tandem s48/45 domains and function at multiple life cycle stages. 
B. p25 utilizes four tandem EGF-like domains for adhesion (left). The four EGF domains are 
shown on the left in different colors for clarity. Extensive contact between p25 monomers was 
observed in the crystal packing arrangement, and these contacts are proposed to play a role in 
parasite surface coat formation (crystal packing arrangement shown on the right). The middle 
p25 monomer, shown in red, is equivalent to the p25 monomer shown on the left, while adjacent, 
contacting monomers are shown in black and grey.  
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C. MSP1-19 contains two tandem EGF-like domains, shown in red, involved in RBC binding. 
MSP1-19 displays extensive contact between the two EGFs, resulting in a rigid structure that 
contrasts other tandem EGF domain structures 
D. CSP Region III-TSR forms a rigid domain designated the α-TSR. Region III (grey) and the 
TSR (green) make extensive contacts. 
E. PfEBA-175 engages its receptor Glycophorin A as a dimer. DBL domains are shown in blue 
for one PfEBA-175 monomer, and in grey for the second monomer that forms the dimeric 
complex during receptor engagement. The parasite membrane is shown in grey; the host RBC 
membrane is shown in red.  
F. Binding of receptor DARC to PvDBP drives dimerization of this complex. The sole DBL 
domain of RII is shown in blue, while the contacting DBL domain from a second PvDBP is 
shown in grey. The parasite membrane is shown in grey; the host RBC membrane is shown in 
red. 
G. PfEBA-140 appears to bind as a monomer to its receptor Glycophorin C. The tandem DBL 
domains of RII are shown in blue. The parasite membrane is shown in grey; the host RBC 
membrane is shown in red. 
H. AMA-1 (orange/brown) binds the parasite expressed RON2 (purple), a member of the RON 
complex, which is released by the parasite into the RBC during invasion. AMA-1 is linked to 
cytoplasmic aldolase (light green) within the parasite. The parasite membrane is shown in grey; 
the host RBC membrane is shown in red. 
I. The link to the parasite’s internal actin motor through cytoplasmic aldolase (light green) is 
formed by TRAP, with functions on the sporozoite. The VWA domain is shown in cyan and the 
TSR domain in green. A unique member of the TRAP family functions at each parasite life stage 
and utilizes a combination of the VWA and TSR domains. The parasite membrane is shown in 
grey; the host cell membrane (mosquito salivary gland and human hepatocyte), is shown in 
yellow. 
J. During growth in the RBC, the parasite exports PfEMP1 to the RBC surface, where these 
proteins utilize a combination of the DBL (blue) and helical CIDR (brown) domains to adhere to 
a wide range of human surface receptors. The N-terminal element (purple) makes extensive 
contact with the DBL domain.  
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invasion 
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2.1 Abstract 
Erythrocyte-binding antigen 140 (PfEBA-140) is a critical Plasmodium falciparum 
erythrocyte invasion ligand that engages Glycophorin C on host erythrocytes during malaria 
infection. The minimal receptor binding region of PfEBA-140 contains two conserved Duffy 
binding- like (DBL) domains, a fold unique to Plasmodia species. Here, we present the crystal 
structure of the receptor binding region of PfEBA-140 at 2.4 angstrom resolution. The two 
domain binding region is present as a monomer in the asymmetric unit, and the structure reveals 
novel features in PfEBA-140 that are likely determinants of receptor specificity. Analysis by 
small-angle X-ray scattering demonstrates that the minimal binding region is monomeric in 
solution, consistent with the crystal structure. Erythrocyte binding assays show that the full 
length binding region containing the tandem DBL domains is required for erythrocyte 
engagement, suggesting that both domains contain critical receptor contact sites. The 
electrostatic surface of PfEBA-140 elucidates a basic patch that constitutes a putative high 
affinity binding interface spanning both DBL domains. Mutation of residues within this interface 
results in severely diminished erythrocyte binding. This study provides insight into the structural 
basis and mechanism of PfEBA-140 receptor engagement and forms a basis for future studies of 
this critical interaction. In addition, the solution and crystal structures allow the first 
identification of likely determinants of erythrocyte receptor specificity for P. falciparum invasion 
ligands. A complete understanding of the PfEBA-140 erythrocyte invasion pathway will aid in 
the design of invasion inhibitory therapeutics and vaccines.  
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2.2 Introduction 
Erythrocyte invasion by Plasmodium species is mediated by integral membrane proteins of 
the erythrocyte binding ligand (EBL) family. During invasion, EBL proteins bind irreversibly 
and specifically to erythrocyte receptors to create a tight junction between host and parasite 
membranes. This interaction facilitates merozoite entry into the red blood cell. Plasmodium 
falciparum has a sophisticated invasion machinery with several EBL proteins that each bind a 
different erythrocyte receptor in a sialic acid dependent manner (Cowman et al., 2006). 
Erythrocyte-binding antigen 175 (PfEBA-175), erythrocyte-binding ligand 1 (PfEBL-1), and 
erythrocyte-binding antigen 140 (PfEBA-140) bind Glycophorin A, B, and C, respectively 
(Orlandi et al., 1992, Lobo et al., 2003, Mayer et al., 2009). A fourth member of this family, 
erythrocyte-binding antigen 181 (PfEBA-181), binds an unknown receptor (Gilberger et al., 
2003). The EBL family members are composed of two cysteine rich regions designated region II 
(RII) and region VI and contain a type I transmembrane domain and short cytoplasmic domain 
(Adams et al., 1992). Receptor binding has been localized to RII for all members. In the P. 
falciparum EBL family, this region contains two tandem Duffy binding- like (DBL) domains, F1 
and F2. The DBL protein fold is unique to Plasmodia, and is able to recognize and tightly bind a 
diverse array of host-cell receptors. In addition to their critical role during invasion, DBL 
domains also mediate microvasculature adherence of infected erythrocytes by erythrocyte 
membrane protein 1 (PfEMP1), a phenomenon directly associated with severe malaria (Kraemer 
et al., 2006).  
It is unknown how the EBL proteins utilize such a highly conserved domain structure to 
recognize different erythrocyte receptors and thus provide P. falciparum with multiple pathways 
for invasion. In addition, the role of each individual erythrocyte invasion pathway during natural 
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infection is not fully understood. However, it has been observed that Gerbich negativity is 
present at high frequency in regions of Papau New Guinea where infection with P. falciparum 
malaria is common (Maier et al., 2003). Gerbich negative individuals have a deletion of exon 3 
in the GPC gene that prevents PfEBA-140 erythrocyte binding and invasion. This observation 
provides strong evidence that severe malaria has selected for this mutation and illustrates the 
significance of erythrocyte invasion mediated by PfEBA-140. 
As the tandem DBL domains in RII of the four P. falciparum EBL proteins can independently 
bind erythrocytes, they are the focus of combinatorial vaccine efforts. To understand how P. 
falciparum uses the DBL protein fold to recognize different erythrocyte receptors during 
invasion, we determined the crystal structure and examined the erythrocyte binding profile of RII 
PfEBA-140. In addition, the solution structure and oligomeric state of this invasion ligand were 
examined using small-angle X-ray scattering (SAXS). The results presented here elucidate likely 
determinants of receptor specificity within the EBL family and provide insight into the structural 
basis of erythrocyte binding by the critical invasion ligand PfEBA-140. 
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2.3 Experimental Procedures 
Protein expression and purification 
A codon-optimized construct containing amino acids 143-740 of RII PfEBA-140 with three 
point mutations (Ser303Ala, Thr469Ala, Ser727Ala) was cloned for expression. The three 
mutations were introduced to avoid aberrant glycosylation at putative N-glycosylation sites 
during expression in mammalian cells that could otherwise impact protein homogeneity. This 
construct provided high yields of pure protein from Escherichia coli and was thus used for 
crystallization. These amino acid changes do not affect protein function, as demonstrated by 
erythrocyte binding assays described below. The construct was expressed as inclusion bodies in 
E. coli and recovered using 6M guanidinium hydrochloride. Following recovery, 100mg/L of 
denatured protein was rapidly diluted in 50 mM Tris pH 8.0, 10 mM EDTA, 200 mM arginine, 
0.1 mM PMSF, 2 mM reduced glutathione, and 0.2 mM oxidized glutathione. After 48 hours of 
refolding at 4ºC, RII PfEBA-140 was concentrated using Amicon centrifugal filters and purified 
by size exclusion and ion-exchange chromatography.  
Crystallization, data collection, and structure determination 
Crystals were grown using the hanging drop vapor diffusion method by mixing 1uL protein 
at 7.5mg/mL with 1uL of reservoir containing 20% PEG 8000 and 0.1 M HEPES pH 7.5. Initial 
crystal hits observed in precipitant screens (Qiagen) were used as seeds to optimize crystal 
growth. Seeds were generated by transferring the entire crystal drop into 10 μl 20% PEG 8000 
and 0.1 M HEPES pH 7.5 and vortexing the sample. Crystals were sent for remote data 
collection at beamline 4.2.2 at the Advanced Light Source, Lawrence Berkeley National 
Laboratory. Cyroprotectant composed of 30% glycerol, 17.5% PEG 8000, and 0.1 M HEPES pH 
7.5 was introduced gradually into the drop by pipetting. Crystals were isolated with nylon loops 
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and stream frozen prior to transport.  
The RII PfEBA-140 structure was solved using molecular replacement using RII PfEBA-175 
as a model in BALBES (Long et al., 2008). Automated refinement was performed with PHENIX 
(Adams et al., 2002) and manual model building was performed with Coot (Emsley et al., 2004). 
Refinement was completed once low R-factors and good geometry were obtained (Table 1). The 
structure described has been deposited in the Protein Data Bank with accession code 4GF2.  
Small-angle X-ray Scattering (SAXS)  
SAXS data was collected at the SIBYLS beamline 12.3.1 at the ALS using standard 
procedures. 30 μl of RII PfEBA-140 at 1 mg ml-1 was automatically loaded into the cuvette with 
a Hamilton Syringe robot (Hura et al., 2009). Radiation damage was assessed by overlaying 
short exposures using PRIMUS (Konarev et al., 2003). CRYSOL (Svergun et al., 1995) was used 
to compare experimental profiles to the crystal structure and DAMMIF was used for ab initio 
model generation (Franke et al., 2009). Structures and SAXS reconstructions were aligned using 
SUPCOMB20 (Kozin et al., 2001). 
Erythrocyte Binding Assay 
RII PfEBA-140 containing the three mutations (Ser303Ala, Thr469Ala, Ser727Ala) was 
fused to a C-Terminal GFP and cloned into pRE4 for surface expression on HEK-293T cells. 
Monolayers of HEK-293T cells grown in 3.5cm wells were transfected with 2.7ug of plasmid 
DNA in polyethyleneimine. The erythrocyte binding assay was performed 20 hours after 
transfection. Transfected cells were incubated with normal human erythrocytes at 2% hematocrit 
for 2 hours. Following incubation, the cells were washed 3 times with Phosphate Buffered Saline 
(PBS). In each experiment, 3 individual wells of HEK-293T cells were transfected with each 
construct. Binding phenotypes were assessed for 10 fields of view from each of the 3 wells of 
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transfected cells (for a total of 30 images for each construct).  
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2.4 Results 
Overall structure of PfEBA-140 Region II 
To define the structural basis of PfEBA-140 receptor specificity, we solved the crystal 
structure of Region II PfEBA-140 (Fig. 1A and Table 1). For simplicity, Region II PfEBA-140 
will be referred as RII PfEBA-140. RII PfEBA-140 is present as a monomer in the asymmetric 
unit, and no oligomeric contacts with potential physiological relevance are observed (Fig. 1A). 
The two DBL domains, F1 (residues 143-422) and F2 (residues 447-740), are connected by a 
short, helical linker. Each DBL domain is composed of three subdomains (Fig. 1B), and contains 
a unique disulfide bridging pattern relative to other DBL family members (Fig. 1C). The F1 and 
F2 domains of PfEBA-140 are structurally similar to other DBL domains of Plasmodium 
invasion ligands (Fig. 1D).  
PfEBA-140 Erythrocyte Binding Requires Both DBL Domains 
The presence of two structurally conserved domains within the minimal binding region 
suggests that each domain may be able to independently engage erythrocytes. To assess the 
function of the individual DBL domains, full length RII PfEBA-140 and constructs containing 
each individual DBL domain were tested for erythrocyte binding by rosetting assay. Full length 
RII PfEBA-140, corresponding to the construct used for crystallization, binds extensively to 
erythrocytes (Fig. 2A). In contrast, neither DBL domain is capable of independently engaging 
erythrocytes (Fig. 2B), suggesting that both domains make essential contacts with GPC during 
invasion. This result is supported by examination of the electrostatic surface of RII PfEBA-140, 
which elucidates a putative high affinity binding interface (Fig. 2C). This region forms an arch of 
overall positive charge that spans the two DBL domains and would provide an ideal interaction 
surface for engagement of the highly glycosylated, acidic GPC.  
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To assess the functional importance of the putative binding interface, individual amino acid 
residues within the basic patch were mutated to alanine and tested for deficient erythrocyte 
binding. Large polar and/or charged residues are often involved in glycoprotein interactions, thus 
we focused on these residues for testing (Fig. 2C). Four residues were identified that when 
mutated to alanine resulted in greatly diminished or null erythrocyte binding (Fig. 2D). This 
result confirms the vital role of individual residues within the putative interface during receptor 
binding. To test the alternate side of the protein, residues on the face opposite of the basic patch 
were also mutated to alanine.  Mutation of these residues had no effect on binding, supporting 
the specific functional role of residues within the basic interface (Fig. 2E).  
The structural basis of PfEBA-140 receptor specificity 
Unique structural elements distinguish RII PfEBA-140 from other DBL domain containing 
EBL ligands and are the likely basis of receptor specificity. All 26 cysteines in RII PfEBA-140 
are involved in disulfide bonds, and two of the disulfide linkages are distinct from other 
characterized DBL domains (Fig. 1C). The modified disulfide pattern includes a linkage between 
cysteine 7 and cysteine 8, as well as a linkage between cysteine 9 and cysteine 12. In contrast, 
linkages between cysteine 7 and cysteine 9 as well as cysteine 8 and cysteine 12 are observed in 
all other characterized EBL members.  
In addition to an altered disulfide pattern, several elements of the RII PfEBA-140 subdomain 
structure are unique among DBL domains. In RII PfEBA-175, β- fingers present in both DBL 
domains contain long loops that serve as critical dimeric contacts required for receptor binding 
(Tolia et al., 2005). In contrast, P. vivax Duffy-binding protein (PvDBP) and P. knowlesi Duffy-
binding protein (PkDBP), which contain only a single DBL domain in their Region II, possess 
short loops within the β- finger region that do not seem to be important for the function of these 
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ligands (Singh et al., 2006, Batchelor et al., 2011). The β- finger of F1 PfEBA-140 is similar in 
length to the β-fingers of the PfEBA-175 F1 and F2 domains. In addition, the F1 β-fingers of 
PfEBA-140 and PfEBA-175 overlay quite well (Fig. 3A). However, the canonical β-finger motif 
in F1 PfEBA-140 is replaced with a novel alpha helical segment in the F2 domain (Fig. 3B).  
A third critical difference is the orientation of subdomain 3 in F1 PfEBA-140 with respect to 
the rest of the DBL domain. In most DBL domains, subdomain 3 contains a kink in a long helix 
facilitated by a glycine residue (Gly185 in F1 PfEBA-175, Gly490 in F2 PfEBA-175, Gly397 in 
PvDBP, Gly394 in PkDBP-α and Gly627 in F2 PfEBA-140). This glycine is absent in F1 
PfEBA-140 and without the inherent flexibility of this residue, the kink in subdomain 3 cannot 
form. The absence of this kink leads to a drastic change within the subdomain that propagates 
through RII PfEBA-140, resulting in a large difference in the hinge angle between the two DBL 
domains compared to RII PfEBA-175 (Fig. 3A and Fig. 3C). The splayed out DBL domains of 
RII PfEBA-140 would require a large hinge movement to create the mode of dimerization seen 
in the crystal structure of RII PfEBA-175 (Fig. 3A, inset).  
Solution structure of PfEBA-140 
The structure and oligomeric state of parasite ligands in solution is an important determinant 
of function. Both the related ligands PvDBP and PfEBA-175 appear to bind receptors as dimers 
(17, 18). We determined the solution structure and oligomeric state of RII PfEBA-140 by SAXS. 
The theoretical scatter for the monomeric PfEBA-140 crystal structure resulted in an excellent fit 
to the experimental SAXS profile with a χ2 of 1.46 (Fig. 4). Furthermore, an averaged ab initio 
reconstruction revealed a molecular envelope that closely resembles the monomeric structure. 
This result is consistent with the observed crystal contacts and hinge angle between the F1 and 
F2 domains suggesting RII PfEBA-140 is monomeric in solution (Fig. 4). Only monomeric 
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forms of PfEBA-140 have been described here and there is no evidence for higher order 
oligomeric states in the absence of GPC.  
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2.5 Discussion 
P. falciparum field isolates from endemic malaria regions actively utilize multiple 
erythrocyte invasion ligands, exemplifying the need to characterize each individual pathway 
(Lobo et al., 2004). Antibodies targeting PfEBA-140 are capable of inhibiting invasion, 
supporting the critical role of this ligand during invasion (Lopaticki et al., 2011). Furthermore, 
PfEBA-140 is naturally immunogenic. Serum isolated from patients infected with P. falciparum 
malaria is reactive to PfEBA-140, and RII was found to be the most immunoreactive element 
(Ford et al., 2007). The active immune response to PfEBA-140 provides strong support for its 
validity as a component of a combinatorial vaccine targeting invasion ligands. The structure 
described here forms a framework for future studies of the critical interaction between PfEBA-
140 and erythrocytes. In addition, identifying the structural basis of receptor specificity within 
the EBL family is essential to characterizing the full range of invasion pathways utilized by P. 
falciparum. These results will thus aid in the rational development of invasion inhibitory 
therapeutics and vaccines. 
The structural differences identified in RII PfEBA-140 suggest an altered mechanism of 
binding relative to PfEBA-175, and likely other EBL members. It has been proposed that 
dimerization is an important mechanistic component of EBL mediated invasion. Support for this 
proposed mechanism comes from the fact that PvDBP is monomeric in the absence of receptor 
and dimerizes upon binding its receptor, DARC (Batchelor et al., 2011). In addition, PfEBA-175 
crystallized as a dimer and may engage GPA in the dimeric form observed in the crystal structure  
(Tolia et al., 2005). It is possible that PfEBA-140 follows this EBL pattern and engages GPC as a 
dimer while existing as a monomer in the absence of receptor. However, to bind GPC using the 
dimer architecture observed for PfEBA-175, RII PfEBA-140 would need to undergo a large 
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structural hinge movement and display dimeric contacts not observed in PfEBA-175. 
Specifically, the β finger motifs in each DBL domain of PfEBA-175 make dimeric contacts. The 
presence of a unique helical element in place of the canonical β finger motif in F2 PfEBA-140 
may alter the dimeric contacts observed in PfEBA-175, resulting in a novel dimer conformation 
of PfEBA-140. It is equally possible that PfEBA-140 engages GPC as a monomer and that 
oligomeric state is an important determinant of receptor specificity.  
Receptor recognition by PfEBA-140 is poorly understood; however, it is known that PfEBA-
140 erythrocyte engagement is dependent on GPC glycans as well as the protein backbone. The 
proposed binding interface identified in the crystal structure spans both DBL domains (Fig. 2C). 
We demonstrated that both domains are required for erythrocyte binding and that mutating 
individual residues in each domain severely diminishes erythrocyte binding. These results 
suggest that each DBL domain forms essential contacts with GPC during invasion. In addition, 
the identification of the positive interface forms a basis for identifying the GPC binding site. It is 
probable that vital receptor binding interactions are located in this putative binding interface due 
to the concentrated presence of basic residues. The only known essential binding component on 
GPC is a solitary N-linked glycan at residue 8 (Mayer et al., 2006). Putative O-linked glycans 
are abundant on GPC, but their role in binding has not been examined in detail. The critical N-
linked glycan may make contacts with both DBL domains, explaining the requirement for full 
length RII during binding. Alternatively, the N-linked glycan may bind with high specificity to 
one domain, while O-linked glycans and the protein backbone form essential contacts with the 
other domain. Further studies examining the interaction of RII PfEBA-140 with GPC are 
required to fully understand the structural and mechanistic basis of receptor recognition during 
invasion. In conclusion, we have provided insight into the PfEBA-140 binding mechanism, 
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elucidated an important receptor binding interface, and identified unique structural motifs in RII 
PfEBA-140 that form the basis of receptor specificity within the EBL family that allows P. 
falciparum to engage multiple host receptors during invasion.  
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2.6 Figures and Tables 
 
 
 
Figure 1. Structure of RII PfEBA-140.A, Overall structure of RII PfEBA-140 as well as the 
location of individual subdomains within each DBL domain.F1 subdomain 1is shown in bronze, 
subdomain 2 in orange, and subdomain 3 in dark orange. F2 subdomain 1 is shown in dark blue, 
subdomain 2 in blue, and subdomain 3 in light blue. The short helical linker between the two 
domains is shown in grey. B, Structures of the individual subdomains in RII PfEBA-140. 
Coloring is the same as in A.C, Representation of the disulfide bridging pattern of characterized 
EBL ligands displaying the two altered disulfides in RII PfEBA-140. D, Overlay of Plasmodium 
invasion ligand DBL domains with each DBL domain of RII PfEBA-140. The top layer displays 
F1 PfEBA-140 in orange; the bottom displays F2 PfEBA-140 in blue. F1 PfEBA-175 is shown in 
dark green, F2 PfEBA-175 in purple, PvDBP in light green, and PkDBP in brown.  
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Figure 2. PfEBA-140 erythrocyte binding requires both DBL domains. A, RII PfEBA-140 was 
expressed on the surface of HEK-293 mammalian cells and tested for erythrocyte binding. GFP 
was utilized to assess proper surface expression. A construct expressing only GFP does not bind 
erythrocytes (top panel). The full length RII construct, identical to the construct used for 
crystallization, is capable of extensively engaging erythrocytes (bottom panel, bound 
erythrocytes appear black around the mammalian cells). B, The individual DBL domains of 
PfEBA-140 were also tested for erythrocyte binding. The F1 (top panel) and F2 (bottom panel) 
DBL domains cannot independently engage erythrocytes. C, The electrostatic surface of PfEBA-
140 RII elucidates a putative high affinity binding interface. The surface of the protein shown in 
the top panel has no clear region of concentrated charged residues (blue: positive charge, red: 
negative charge). However, when rotated 180 degrees, a region of positive charge that forms an 
arch between the two DBL domains is illuminated (middle panel). Surface charge potential is 
colored from +3.5eV to -3.5eV. The bottom panel displays the face of the protein containing 
basic patch identified as a putative binding interface. Residues mutated to alanine and tested for 
erythrocyte binding are identified with arrows and shown in black.  D, Alanine mutations within 
the basic patch disrupt erythrocyte binding. E, In contrast to residues within the basic patch, 
alanine mutations on the opposite face of RII PfEBA-140 do not disrupt erythrocyte binding. 
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Figure 3. Structural determinants of receptor specificity within the EBL family. A ,Overlay of 
PfEBA-140 (F1 domain in orange, F2 domain in blue) with PfEBA-175 (F1 domain in green, F2 
domain in purple). The conserved F1 beta sheet motifs are outlined in black. The inset o utlined 
in black displays two monomers of PfEBA-140 overlayed onto the PfEBA-175 dimer observed 
in the crystal structure (17). B, Overlay of the PfEBA-140 F1 and F2 DBL domains (left). The 
altered helical element in F2 is outlined in black. A close up view of this F2 helical element, 
overlayed onto the F1 beta sheet, is shown on the right. C,View of the altered helical orientation 
of F1 RII PfEBA-140 subdomain 3 (orange). This orientation occurs due to the absence of a 
glycine, which is conserved in other EBL members, at residue 325 in PfEBA-140. The kink 
observed in F1 PfEBA-175 (green) is shown for comparison.  
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Figure 4. Oligomeric state of RII PfEBA-140. RII PfEBA-140 is monomeric in solution in the 
absence of receptor. Shown here are the experimental and theoretical SAXS plots of scattering 
intensity versus scattering momentum. The inset displays an ab initio construct of PfEBA-140 
(light blue) overlayed onto the crystal structure (F1 domain in orange, F2 domain in blue).  
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Table 1: Data collection and refinement statistics  
 
 RII PfEBA-140  
Data collection  
Space group P21 
Cell dimensions  
a, b, c (Å) 65.42, 76.48, 82.34 
    α, β, γ (º)  90.00, 96.80, 90.00 
Resolution (Å) 20-2.4 (2.49-2.40)  
Rmerge 5.8% (78.9%) 
I /σI 19.06 (2.07) 
Completeness (%) 99.4% (98.0%) 
Redundancy 3.72 (3.67) 
  
Refinement  
Resolution (Å) 20.0-2.4 
No. reflections 31,507 
Rwork / Rfree (%) 20.03 / 23.69 
No. atoms  
    Protein 5,339 
    Ligand/ion 90 
    Water 143 
B-factors  
    Protein 67.57 
    Ligand/ion 78.16 
    Water 53.73 
R.m.s. deviations  
    Bond lengths (Å) 0.003 
    Bond angles (º) 0.607 
Ramachandran  
    Favored 97.46% 
    Allowed 2.54% 
    Disallowed 0.00% 
Values in parentheses are for highest-resolution shell. 
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Chapter 3   
 
The molecular basis for sialic acid dependent receptor 
recognition by PfEBA-140
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3.1 Abstract 
Plasmodium falciparum erythrocyte invasion is dependent on high-affinity recognition of 
sialic acid on cell-surface receptors. The Erythrocyte Binding- like (EBL) family of invasion 
ligands mediates recognition of sialic acid on erythrocyte glycoproteins. Erythrocyte Binding 
Antigen-140 (PfEBA-140/BAEBL) is a critical EBL ligand that binds sialic acid on its receptor 
Glycophorin C. We present here the crystal structure of the two domain receptor-binding region 
of PfEBA-140 in complex with a glycan containing sialic acid. The structure identifies two 
glycan-binding pockets unique to PfEBA-140 and not shared by other EBL ligands. Specific 
molecular interactions that enable receptor engagement are identified and reveal that the glycan-
binding mode is distinct from that of Apicomplexan and viral cell surface recognition ligands as 
well as host immune factors that bind sialic acid. Erythrocyte binding experiments elucidated 
essential glycan contact residues and identified divergent functional roles for each receptor 
binding site. One of four polymorphisms proposed to affect receptor-binding was localized to a 
glycan binding site, providing a structural basis for altered erythrocyte engagement. The studies 
described here provide the first full description of sialic acid-dependent molecular interactions at 
the P. falciparum erythrocyte invasion interface and define a framework for development of 
PfEBA-140 based therapeutics, vaccines, and diagnostics assessing vaccine efficacy and natural 
immunity to infection. 
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3.2 Introduction 
Plasmodium falciparum erythrocyte invasion requires targeted recognition of cell surface 
receptors by merozoite ligands (Camus et al., 1985, Sim et al., 1990). High affinity binding to 
erythrocyte receptors is critical to the invasion process and is mediated by the Erythrocyte 
Binding- like (EBL) family of proteins (Adams et al., 1992). In P. falciparum the EBL family is 
composed of four known functional membrane embedded ligands that each target a specific 
erythrocyte receptor in a sialic acid dependent manner (Adams et al., 1992). Receptor 
engagement by the merozoite allows the formation of an irreversible tight junction with the host 
membrane and subsequent formation of the parasitophorous vacuole (Dvorak et al., 1975, 
Aikawa et al., 1978). Binding interactions mediated by the EBL family are vital to the survival of 
the parasite and are thus targets of therapeutics and vaccines (Aravind et al., 2003, Cowman et 
al., 2006). 
Each member of the P. falciparum EBL family contains an extracellular cysteine rich region 
composed of two Duffy binding- like (DBL) domains designated F1 and F2 (Mayor et al., 2005). 
These two domains comprise the minimal binding region of the P. falciparum EBL ligands, and 
have been designated Region II (RII). P. falciparum Erythrocyte Binding Antigen 140 (PfEBA-
140/BAEBL) is a member of the EBL family that binds erythrocytes via its cell surface receptor 
Glycophorin C (GPC) (Lobo et al., 2003). Studies examining the erythrocyte binding capability 
of the individual RII PfEBA-140 DBL domains (F1 and F2) demonstrated that neither domain is 
sufficient to engage erythrocytes (Mayer et al., 2002, Lin et al., 2012). In addition, single amino 
acid mutations in either DBL domain severely disrupt erythrocyte binding, demonstrating an 
essential role for both DBL domains during invasion (Lin et al., 2012).  
Receptor recognition by P. falciparum invasion ligands is also characterized by the 
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sensitivity of the binding interaction to specific enzyme treatments of red blood cells (Miller et 
al., 1977, Mayer et al., 2001). Reports examining the binding profile of PfEBA-140 to enzyme 
treated erythrocytes have provided a basic understanding of how this ligand engages its receptor. 
PfEBA-140 receptor binding is trypsin and neuraminidase sensitive, but chymotrypsin resistant 
(Mayer et al., 2001). In addition, soluble sialic acid is not capable of inhibiting PfEBA-140 
erythrocyte binding (Mayer et al., 2001). These results demonstrated that receptor glycans 
containing sialic acid are essential for receptor recognition, and that the protein backbone of 
GPC also plays a role in binding (Mayer et al., 2001, Narum et al., 2002, Jiang et al., 2009).  
GPC possesses several putative O-linked glycans and one known N-linked glycan, all containing 
the sialic acid sugar moiety required for PfEBA-140 binding. The solitary N-linked glycan is 
essential for GPC engagement, but the role of individual O- linked glycans is not clear (Mayer et 
al., 2006).  
Numerous and widespread polymorphisms have been identified in Plasmodium invasion 
ligands, specifically PfEBA-175 and P. vivax Duffy Binding Protein (PvDBP) (Xainli et al., 
2000, Baum et al., 2003, Gosi et al., 2008). In contrast, only four polymorphic residues have 
been identified in RII PfEBA-140, all of which are present in the F1 domain: Ile185Val, 
Asn239Ser, Lys261Arg/Thr, and Lys285Glu (Mayer et al., 2002). Polymorphic residue changes 
in PfEBA-140 modify this ligand’s binding profile to enzyme-treated erythrocytes. The altered 
binding profile suggests that PfEBA-140 is capable of interacting with other erythrocyte cell 
surface molecules and may mediate an invasion process independent of GPC (Thompson et al., 
2001, Mayer et al., 2002). In addition to altering the binding profile, it has been shown that 
polymorphisms reduce the affinity of PfEBA-140 for erythrocytes (Maier et al., 2009). Recent 
evidence suggests that binding to glycosaminoglycans (GAGs) on the erythrocyte surface 
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promotes merozoite invasion (Boyle et al., 2010). PfEBA-140 is capable of binding heparin, and 
it has been proposed that cell surface GAGs may function as a secondary interaction element 
during PfEBA-140 mediated invasion (Kobayashi et al., 2010). 
The role of individual EBL invasion ligands during in vivo erythrocyte invasion and blood 
stage growth is not fully understood. However, several studies have demonstrated the importance 
of PfEBA-140 during natural infection as both an invasion ligand and antigen. Individuals in 
malaria endemic regions mount a strong antibody response to PfEBA-140, and RII was the most 
immunoreactive element (Ford et al., 2007). This result provides evidence of PfEBA-140 
expression and immune recognition in natural infections and supports the significance of this 
ligand as a member of a combinatorial vaccine. In addition to natural immunogenicity, antibodies 
targeting RII PfEBA-140 are capable of inhibiting invasion, which is strongly supportive of the 
functional role and antigenic properties of PfEBA-140 (Maier et al., 2003, Lopaticki et al., 
2011). Furthermore, Gerbich negativity is observed at high frequencies in regions of endemic 
malaria in Papau New Guinea (Maier et al., 2003). This phenotype results from the loss of exon 
3 within the GPC gene. The absence of this portion of GPC prevents PfEBA-140 from engaging 
erythrocytes and thus inhibits the invasion process. The prevalence of Gerbich negativity 
provides evidence that severe malaria has selected for this mutation and supports the importance 
of PfEBA-140 during natural infection (Maier et al., 2003). 
To identify receptor binding sites in PfEBA-140 and define molecular interactions at the 
merozoite-erythrocyte invasion interface, we solved the crystal structure of RII PfEBA-140 in 
complex with a glycan containing sialic acid, the essential sugar component of GPC that is 
recognized during erythrocyte engagement. Two glycan binding pockets are identified, one in 
each DBL domain. Mutation of individual sialic acid contact residues disrupts erythrocyte 
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binding by RII PfEBA-140, confirming the functional role of the sugar binding pockets. Stark 
differences in the mutant erythrocyte binding phenotypes for the F1 and F2 domains suggest that 
each DBL domain performs a distinct function during erythrocyte engagement. One of the four 
polymorphic residues that affect PfEBA-140 receptor-binding is found in the base of the F1 
glycan binding pocket. The localization of this residue provides insight into the structural basis 
of altered receptor binding observed for polymorphic variants. The structure also allowed for 
mapping of putative sulfate and GAG binding sites, which may represent true interaction 
elements that promote red blood cell binding and invasion. This study provides the first complete 
molecular and structural description of sialic-acid dependent interactions critical to the formation 
of the tight junction at the merozoite-erythrocyte invasion interface. Our results will thus aid in 
the design of novel therapeutics and diagnostics targeting this essential step in the parasite’s life 
cycle. 
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3.3 Experimental Procedures 
Protein expression and purification 
RII PfEBA-140 was expressed and purified as previously described (Lin et al., 2012). 
Briefly, RII PfEBA-140 was expressed in Escherichia coli and recovered from inclusion bodies 
using 6M guanidinium hydrochloride. After overnight denaturing, 100mg/L of denatured protein 
was rapidly diluted in 50 mM Tris pH 8, 10 mM EDTA, 200 mM arginine, 0.1 mM PMSF, 2 mM 
reduced glutathione, and 0.2 mM oxidized glutathione. The protein was refolded for 48 hours at 
4ºC. After refolding, RII PfEBA-140 was purified by ion-exchange and size exclusion 
chromatography and concentrated using Amicon centrifugal filters for crystallization.  
Crystallization, data collection, and structure determination 
 Crystals of RII PfEBA-140 were grown using the hanging drop vapor diffusion method. The 
drops were produced by mixing 1uL of protein at 7.5mg/mL with 1uL of reservoir containing 
20% PEG 8000 and 0.1 M HEPES pH 7.5. Crystals of RII PfEBA-140 alone were soaked with 
10mM sialyllactose for 30 minutes to obtain the complex. Crystals were sent for remote data 
collection in cryoprotectant composed of 30% glycerol, 17.5% PEG 8000, and 0.1 M HEPES pH 
7.5. The cryoprotectant was introduced gradually into the drop by pipetting and crystals were 
isolated with nylon loops and stream frozen prior to transport. Data was collected at beamline 
19-ID at the Advanced Photon Source, Argonne National Laboratory and processed with XDS 
(Kabsch, 2010). The structure of RII PfEBA-140 bound to sialyllactose was solved using the 
unbound PfEBA-140 structure PDB 4GF2 as a model in Phaser (McCoy et al., 2007, Lin et al., 
2012). Refinement and model building were performed with PHENIX (Adams et al., 2002) and 
Coot (Emsley et al., 2004) and refinement was completed once low R-factors and good geometry 
were obtained (Table 1). The structure described has been deposited in the Protein Data Bank 
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with accession code 4JNO.  
Functional studies 
RII PfEBA-140 was fused to a C-Terminal GFP in plasmid pRE4 for surface expression on 
HEK-293T cells. Individual alanine point mutants were produced using the QuikChange method 
and verified by plasmid sequencing. Monolayers of HEK-293T cells grown in 3.5cm wells were 
transfected with 2.7ug of plasmid DNA in polyethyleneimine. Erythrocyte binding of individual 
constructs was assayed 20 hours after transfection.  
To assess the binding phenotypes of RII PfEBA-140 mutant constructs, transfected HEK-293 
cells were incubated with normal human erythrocytes. For enzyme treatment experiments, 
normal erythrocytes at 50% hematocrit were treated with 0.1mg/mL trypsin, 0.1mg/mL 
chymotrypsin, or 5mU of Vibrio cholera neuraminidase at 37ºC for 2 hours and washed prior to 
use. Erythrocytes at 2% hematocrit were then overlayed onto the transfected HEK-293 cells for 2 
hours. Following incubation with untreated or enzyme treated erythrocytes, the transfected HEK-
293 cells were washed 3 times with Phosphate Buffered Saline (PBS) to remove unbound 
erythrocytes. For the mutation studies, three individual wells of HEK-293 cells were transfected 
with each mutant construct. Binding percentage was calculated as the number of rosette positive 
cells over the number of GFP positive cells and was normalized to wild type binding. Binding 
phenotypes were quantified over 10 fields of view from each of the 3 wells of transfected cells (a 
total of 30 images for each construct). Images were obtained using a Zeiss LSM 510 META 
Laser Scanning Microscope with an LD Achroplan 20X Korr DIC objective. Images were 
randomized prior to counting with ImageJ.  
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3.4 Results 
Identification of two glycan binding sites in RII PfEBA-140 
To identify receptor binding pockets, we solved the crystal structure of RII PfEBA-140 in 
complex with α-2,3-sialyllactose (Data collection and refinement statistics presented in Table 1). 
The glycan, α-2,3-sialyllactose, is a trisaccharide composed of sialic acid, galactose, and glucose 
and thus contains the critical sugar groups present on GPC that are required for binding 
(Neu5Ac(α-2,3)-Gal). RII PfEBA-140 bound to siallylactose is present as a monomer in the 
asymmetric unit, consistent with the solution and crystal structures of unbound RII PfEBA-140 
(Lin et al., 2012). Clear density was observed for the sialic acid of two siallylactose molecules in 
the co-crystal structure, with one molecule contacting each DBL domain. The sialic acid moieties 
were modeled into the two binding sites (Fig. 1, A-D). Average B-factors for the sialic acids in 
both pockets were comparable (64.42 and 64.04 Å2), suggesting similar occupancy and affinity. 
Additional density was observed for the galactose of each sialyllactose molecule, but due to 
inherent flexibility galactose could not be adequately modeled. The galactose density extends out 
of both pockets and away from the contact surface (Fig. 1, B and C), supporting the importance 
of contacts between sialic acid and PfEBA-140. The two binding sites are present within a region 
spanning both DBL domains that contains a concentration of positively charged residues 
previously identified as a putative receptor binding region (Fig. 1D) (Lin et al., 2012). The 
glycan binding sites are in a structurally similar position on the F1 and F2 domains, with the 
sialic acid inserting into a valley at the interface of a helix and an extended loop (Fig. 1, E and 
F). 
The sialic acid moiety contains a pyranose ring with single carboxyl, glycerol, and acetamido 
functional groups. The pyranose ring and functional groups of the bound sialic acid insert into 
65 
 
the F1 binding pocket and several contact residues form a cup- like interaction with the glycan 
(Fig. 2A). In the base of the pocket Gln182 hydrogen bonds and forms van der Waal’s 
interactions with the sialic acid carboxyl. Contacts with the sialic acid glycerol chain are 
mediated by Arg158, which forms a hydrogen bond and is involved in van der Waals contacts 
with hydroxyl groups. On the opposite face of the binding pocket, the sialic acid acetamido 
group is oriented towards a helix containing Asn251. This helix places Asn251 in proper 
orientation to hydrogen bond with the 4-hydroxyl of the pyranose ring. In addition to the 
aforementioned contact surfaces, Ile181 and Ile185 form the base of the pocket and interact with 
hydrophobic regions of the sugar.  
The F2 binding site contains a glycan contact surface that is similar to that observed in the F1 
domain (Fig. 1F). However, the pocket residues are altered such that the observed glycan 
contacts are distinct (Fig. 2B). Asn457 forms contacts not observed in the F1 pocket as a result of 
its location on a loop at the top of the binding site. This orientation allows Asn457 to form van 
der Waal’s interactions with the glycan carboxyl. Interactions with the sialic acid glycerol chain 
are mediated by Lys464, which hydrogen bonds with a hydroxyl group and engages in van der 
Waal’s contacts with the sugar. Thr487 is present in the base of the pocket and contacts 
hydrophobic regions of the glycan. A helix containing Tyr556, analogous to the helix carrying 
Asn251 in the F1 pocket, extends the side chain of Tyr556 towards the glycan to engage in 
hydrophobic contacts with the sialic acid acetamido group.  
Distinct functional roles for each glycan binding pocket 
To examine the receptor specificity of the RII PfEBA-140 construct used for crystallization, 
we assessed the binding phenotype with enzyme treated erythrocytes. The rosetting interaction is 
sensitive to neuraminidase and trypsin treatment, but resistant to chymotrypsin, consistent with 
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previously observed results for RII PfEBA-140 (Fig. 2C) (Mayer et al., 2001, Narum et al., 
2002, Maier et al., 2009). These results confirm that the interaction is sialic acid dependent and 
support the specificity of the recombinant construct for GPC on the erythrocyte surface.  
To determine the role of specific sialic acid interactions identified in the crystal structure, 
individual glycan contact residues were mutated to alanine and the mutant constructs were tested 
for erythrocyte binding. Mutating individual contact residues in the F1 pocket severely 
diminished erythrocyte binding, suggesting that F1 glycan contacts are critical for receptor 
recognition (Fig. 2, D and F). In the absence of contacts mediated by Arg158 or Gln182, 
erythrocyte binding does not occur, suggesting that these residues are essential for binding 
interactions. The helix that presents the side chain of Asn251 is supportive for binding and it is 
likely that this helix plays an important role in maintaining the structure of the binding pocket. 
The hydrophobic base of the pocket, composed primarily of Ile181, is crucial for erythrocyte 
binding. The observed binding deficiency upon mutating Ile181 to alanine is likely due to its role 
in maintaining normal binding site conformation and engaging in strong hydrophobic contacts 
with the glycan.  
In contrast to the severe phenotypes observed for alanine mutations in the F1 binding pocket, 
mutations in the F2 binding site resulted in a modest reduction in erythrocyte binding (Fig. 2, E 
and G). Mutation of Lys464 to alanine resulted in a 9.3% decrease in binding while mutation of 
other residues to alanine in the F2 pocket did not alter the erythrocyte binding phenotype. 
However, it is possible that a single mutation to alanine is insufficient to disrupt the function of 
this binding site. To further examine the functional role of glycan contacts in the F2 binding 
pocket, two residues were mutated to glutamate to induce charge repulsion with the sialic acid. 
Individually mutating Lys464 or Tyr556 to glutamate resulted in a 30.6% and 32.5% decrease in 
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binding, respectively. The F2 binding pocket is also close to residues in a basic patch (Arg485 
and Asp554) that when mutated individually to alanine drastically reduce binding to erythrocytes 
(see Fig. 2B) (Lin et al., 2012). Together, these results suggest that the F2 binding site recognizes 
sialic acid in a functional, but non-essential manner and that the F2 sialic acid binding pocket 
and surrounding residues contact GPC. Reduced erythrocyte binding of alanine and glutamate 
mutants was not due to inefficient surface expression of RII PfEBA-140 as expression was 
monitored by GFP (Fig. 2, C-E). In addition, Lys347 was mutated to alanine as a surface control 
and displays wild type binding.  
PfEBA-140 glycan binding contacts are unique among sialic acid binding proteins  
The glycan contacts observed in the two PfEBA-140 binding pockets are unique when 
compared to other proteins that require cell surface sialic acids for binding. In addition to 
Plasmodium species, other Apicomplexan parasites, including Toxoplasma gondii, actively 
invade host cells during infection. Invasion by T. gondii is mediated by micronemal proteins 
(MICs). A member of this group, TgMIC1, recognizes sialic acid derivatives on the cell surface 
(Blumenschein et al., 2007). Glycan recognition by TgMIC1 requires contact with the sialic acid 
carboxyl group mediated by a threonine conserved in the TgMIC1 protein fold (Fig. 3A). 
Recombinant TgMIC1 does not bind host cells when this threonine is mutated to alanine, 
confirming the essential role of this residue (Blumenschein et al., 2007). In addition to the 
threonine, a histidine interacts with the carboxyl group and a tyrosine forms the base of the sialic 
acid binding pocket. The overall structure of the sialic acid binding site and the critical contact 
residues are thus distinct from both binding sites of PfEBA-140 (Fig. 3A).  
In addition to Apicomplexan parasites, other pathogens recognize cell surface sialic acids 
during infection. All subtypes of the Influenza virus bind to host cells in a sialic acid dependent 
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manner mediated by the surface protein hemagglutinin. The conserved hemagglutinin sialic acid 
binding site utilizes essential glycerol chain contacts and hydrophobic interactions with the 
acetamido group to engage the glycan (Fig. 3B). Contacts with the carboxyl appear to be 
supportive (Watowich et al., 1994, Skehel et al., 2000, Ha et al., 2001). In comparison, although 
glycerol contacts are essential to PfEBA-140 binding, the binding site structures and interacting 
residues are distinct. In addition, interactions with the sialic acid carboxyl are critical for PfEBA-
140, but not hemagglutinin binding.  
Sialic acid is also required for a number of interactions involving proteins that modulate 
immune function, including selectins and Siglecs (Varki et al., 2007). Selectins interact most 
extensively with the sialic acid carboxylate and glycosidic oxygen and also contact the 4-
hydroxyl of the pyranose ring (Fig. 3C). Contact with other functional groups does not appear to 
be important for selectin binding (Somers et al., 2000). This mode of contact sharply contrasts 
with that of PfEBA-140, which interacts with each functional group and requires both the 
carboxyl and glycerol moieties to effectively engage the glycan. The PfEBA-140 binding sites 
are also distinct from that of the Siglecs. Siglec binding is dependent on a salt bridge formed 
with the sialic acid carboxyl group and van der Waal’s contacts with the acetamido methyl group, 
mediated by a conserved arginine and semiconserved tryptophan/tyrosine, respectively (Fig. 3 D) 
(Attrill et al., 2006, Crocker et al., 2007). Although other sialic acid binding proteins utilize 
contacts that resemble those observed in RII PfEBA-140, the GPC binding sites are distinct and 
represent a novel mode of glycan contact.  
Structural basis for altered receptor-binding caused by polymorphic residues 
Polymorphisms in PfEBA-140 are thought to reduce affinity to GPC (Maier et al., 2009) and 
have been proposed to alter PfEBA-140 receptor specificity (Mayer et al., 2002). One of the 
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identified polymorphisms, Ile185, is buried in the critical F1 binding pocket (see Fig. 2A). 
Variants that contain a valine in place of isoleucine at position 185 display reduced binding to 
erythrocytes and GPC (Maier et al., 2009). The F1 binding pocket forms a tight fit with high 
shape complementarity to the sialic acid when isoleucine is present at position 185 (Fig. 4A). To 
examine the effect of a valine mutation, Ile185 was mutated to valine in silico. This mutation 
opens a cavity at the base of the pocket adjacent to the 4-hydroxyl of the pyranose ring (Fig.4B). 
Mutation to valine in vivo likely alters the pocket surface in this manner, reducing shape 
complementarity and increasing solvent accessibility to both the pocket and the glycan. This 
change would disrupt glycan binding and provides a structural basis for diminished affinity of 
polymorphic PfEBA-140 variants for erythrocytes (Maier et al., 2009). The structural alteration 
also elucidates a putative basis for altered receptor specificity.  
Glycan binding induces a helix shift in the F2 domain 
The structure of RII PfEBA-140 bound to sialyllactose maintains the same overall 
architecture and hinge angle as unbound RII (Fig. 5A). Glycan binding did not result in any large 
structural changes in the F1 domain, but caused a helix containing Thr493, Tyr494 and Leu495 
to move away from the binding pocket of the F2 domain (Fig. 5B). The bound sialic acid in the 
F2 domain inserts into a cavity containing two water molecules in the unbound structure. Glycan 
binding blocks access of the water molecules at this position, d isrupting main chain contacts and 
destabilizing the helix such that the helix movement is possible (Fig. 5C). The glycan induced 
movement in the F2 domain may provide access to the highest affinity interface for GPC.  
Putative sulfate-binding motifs map close to the glycan binding pockets 
In addition to binding GPC, RII PfEBA-140 is capable of interactions with heparin and 
potentially with cell surface GAGs. Heparitinase treatment of erythrocytes inhibits RII PfEBA-
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140 binding, providing support for a potential interaction with cell surface GAGs such as 
heparan sulfate (Kobayashi et al., 2010). These observations suggest that GAGs on the 
erythrocyte surface interact with PfEBA-140 and may promote invasion. RII PfEBA-140 
contains five putative sulfate-binding motifs that can potentially bind GAGs, three of which are 
adjacent to the identified sialic acid binding sites in F1 and F2 (Fig. 5D). Mutation of the 
adjacent sulfate-binding motifs 1 and 4 greatly diminishes erythrocyte binding. The effect of 
mutating motif 2 has not been examined. In contrast to the adjacent motifs 1 and 4, mutation of 
sulfate-binding motifs 3 and 5, which are distal to the glycan binding sites, has little or no effect 
on erythrocyte binding (Kobayashi et al., 2010). Thus, it is plausible that sulfate-binding sites 1, 
2, and 4 represent true interaction elements that may play a role in facilitating invasion. While 
the putative sulfate-binding motifs are proposed to engage heparan sulfate (Kobayashi et al., 
2010), additional sulfate containing molecules such as sulfatides, sulfated glycolipids, 
glycoprotein oligosaccharides, and chondroitin sulfate proteoglycans exist on erythrocytes. It is 
possible that putative sulfate-binding motifs 1, 2, and 4 may interact with any or all of these 
moieties. 
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3.5 Discussion 
The results presented here represent the first molecular description of specific interactions an 
EBL protein utilizes to recognize and bind sialic acid. Although DBL domains have been 
crystallized with sugars previously, the crystal structure of RII PfEBA-140 presented here 
represents the first full modeling of sialic acid into a DBL domain sugar binding site. This  
modeling allowed identification of two receptor binding sites and elucidation of critical 
molecular interactions that the parasite utilizes to form the essential tight junction with the host 
erythrocyte membrane during invasion. Mapping molecular contacts demonstrated that PfEBA-
140 recognizes sialic acid on receptor glycans utilizing unique interactions compared to its 
paralog PfEBA-175 as well as compared to viral cell invasion and host immune proteins that also 
engage sialic acid. The bound structure also provided insight into the role of polymorphisms in 
altering receptor binding and illuminated the location of putative sulfate-binding motifs that may 
engage GAGs or other sulfate-containing surface molecules. The importance of these moieties 
during invasion is unclear, but localizing their binding sites within RII provides a basis for future 
studies examining their function during Plasmodium invasion. 
The identification and description of receptor binding sites within PfEBA-140 allows for 
direct comparison with the glycan binding sites of other DBL domains. DBL domains function in 
a number of settings including erythrocyte invasion and cytoadherence of infected erythrocytes 
mediated by Erythrocyte Membrane Protein 1 (PfEMP1) (Kraemer et al., 2006). The two glycan 
binding regions of RII PfEBA-140 are structurally distinct from receptor-binding regions of 
PfEBA-175, PvDBP, PfEMP1 DBL3X and the PfEMP1 VarO head region, and thus represent 
novel receptor-binding sites for the DBL fold (Tolia et al., 2005, Singh et al., 2008, Batchelor et 
al., 2011, Vigan-Womas et al., 2012). Specifically, the glycan interactions observed in RII 
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PfEBA-175 are limited to the dimer interface (Tolia et al., 2005). In contrast, formation of the 
glycan binding sites in RII PfEBA-140 does not require dimerization (Fig. 6). We previously 
demonstrated that RII PfEBA-140 is monomeric in solution in the absence of receptor (Lin et al., 
2012). RII PfEBA-140 has been observed only as a monomer in solution and crystal forms, and 
the lack of dimerization in the presence of siallylactose suggests that PfEBA-140 may engage 
GPC as a monomer. Studies examining the oligomeric state of PfEBA-140 in the presence of 
GPC are required to fully understand the mechanism of receptor engagement and specificity. In 
addition to the different oligomeric states observed upon sialic acid binding for PfEBA-175 and 
PfEBA-140, the location within the DBL domain and overall structure of the binding pockets is 
distinct (Fig. 6). Furthermore, PfEBA-175 contains six glycan binding sites per dimer, in contrast 
to two observed for the monomer of PfEBA-140. It is likely that the novel modes of contact 
observed for PfEBA-140 confer specificity for sialic acid moieties present on GPC over 
Glycophorin A or B, and suggests how structurally similar DBL domains specifically recognize 
diverse receptors. 
In addition to structural and molecular contrasts with the glycan binding sites of DBL 
domains, this work allows for comparison with other Apicomplexan invasion proteins that 
recognize cell surface sialic acid. As shown in Figure 3A, sialic acid recognition by TgMIC1 is 
quite distinct when compared to PfEBA-140. In addition, there is no structural similarity in the 
overall protein fold of the minimal binding regions of TgMIC1 and PfEBA-140 (Blumenschein 
et al., 2007). However, both proteins contain two tandem, conserved domains comprising the 
minimal binding region, with each domain containing a single sialic acid binding site on the 
same face of the protein. This resemblance suggests some functional similarities in their mode of 
glycan engagement (Blumenschein et al., 2007). The Plasmodium merozoite is specifically 
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marked for the erythrocyte, unlike T. gondii, which is capable of invading any nucleated cell. It 
thus appears that TgMIC1 has developed a sialic acid binding mode that allows recognition a 
broad range of glycans during cell binding, sharply contrasting the proposed erythrocyte sialic 
acid glycan specificity of PfEBA-140. PfEBA-140 receptor specificity may thus be conferred by 
a unique glycan composition on the erythrocyte surface combined with essential interactions 
with the GPC protein backbone.  
The erythrocyte binding phenotypes observed upon mutation of contact residues in each 
glycan pocket suggest distinct roles for the individual DBL domains of RII PfEBA-140 during 
erythrocyte binding. GPC contains several O-linked glycans and a single N-linked glycan, each 
with the essential sugar moiety Neu5Ac(α-2,3)-Gal. Recognition of the N-linked glycan is 
essential to the interaction (Mayer et al., 2006). Thus, interactions with the N-linked glycan may 
be mediated solely by the F1 sialic acid binding site. The null and severely deficient bind ing 
phenotypes observed upon mutation of contact residues in the F1 pocket could be the result of 
losing the critical interaction with the N-linked glycan.  
Receptor contacts with the F2 domain are also required for erythrocyte binding as neither 
individual DBL domain is sufficient to bind erythrocytes independently (Mayer et al., 2002, Lin 
et al., 2012). The observation that only mutations to glutamate in the F2 binding pocket reduced 
binding efficiency may be explained by compensatory interactions between the glycan and other 
binding site residues. In addition to glycan contacts, PfEBA-140 erythrocyte binding is 
dependent on the GPC protein backbone. It is thus also plausible that F2 engages in strong 
contacts with additional regions of GPC and that glycan interactions are supportive but not 
essential in maintaining this interaction.  
In addition to invading via GPC, it has been proposed that polymorphic variants of PfEBA-
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140 are capable of invading using an alternative receptor. The identification of Ile185 in the F1 
binding pocket suggests that polymorphism at this residue may play an important role in 
determining receptor affinity and possibly specificity. Our studies suggest a model to explain the 
altered binding profile of polymorphic variants. The proximity of the glycan binding pockets and 
sulfate-binding motifs 1, 2 and 4 suggest that GPC binding precludes GAGs or sulfate-containing 
molecules from accessing these sugar binding sites. This proposal is supported by the fact that 
the helix containing sulfate-binding motif 4 is shifted upon sialyllactose binding (see Fig. 5, A 
and B). It is plausible that a valine mutation at position 185 destabilizes the F1 binding pocket, 
reducing affinity for sialic acid and opening sulfate-binding motifs 1 and 2 for functional GAG 
binding. The altered surface observed following in silico mutation of Ile185 to valine supports 
the destabilization hypothesis (see Fig. 4). It is equally possible that a secondary sialylated 
receptor is recognized by specific variants of PfEBA-140 during invasion. 
The structural and functional data described here have provided a detailed molecular 
description of sialic acid recognition by an EBL family erythrocyte invasion ligand, PfEBA-140. 
Preventing erythrocyte receptor engagement provides an excellent opportunity to inhibit 
merozoite invasion and blood stage growth of the parasite. The identification of critical 
interactions at the invasion interface will thus aid in the design of rational therapeutics and 
vaccines that target the EBL ligands.  
  
75 
 
3.6 Figures and Tables 
  
Figure 1. The crystal structure of RII PfEBA-140 bound to sialyllactose reveals two receptor 
glycan binding sites. A, RII PfEBA-140 bound to two sialyllactose molecules in the crystal 
structure. The F1 and F2 DBL domains each form a contact surface with one sialyllactose 
molecule. The F1 domain is shown in orange, the F2 domain in blue. A short linker connecting 
the two DBL domains is shown in grey. The modeled sialic acid molecules in each glycan 
contact site are shown in green and boxed in black. B, The bound sialic acid inserts into the F1 
and F2 binding pockets while the galactose extends away from the pocket surface. The sialic acid 
molecules and corresponding electron density observed in the F1 domain (left, orange) and F2 
domain (right, blue) are displayed within their binding sites. The sialic acid is shown in red for 
clarity. Density for the galactose is shown to illustrate the location of this sugar moiety relative to 
the sialic acid binding site. The Fo-Fc map prior to sialic acid modeling is shown in green and 
contoured at 3.0σ. The 2Fo-Fc map obtained following modeling of the sialic acid into the 
binding pocket is shown in blue and contoured at 1.0σ. C, Close-up view of the electron density 
observed for the sialic acid and galactose of the bound siallylactose in the F1 (left) and F2 (right) 
domains. The density maps are contoured and colored as in B. D, The two glycan binding sites 
are located in a region of concentrated positively charged residues that may function as a high 
affinity interface for GPC engagement. Surface charge potential is colored from +3.5eV (blue) to 
-3.5eV (red). E, The sialic acid binding pockets are in structurally similar locations on the F1 and 
F2 DBL domains. The glycan bound to the F1 domain is shown in green, the glycan bound to the 
F2 domain is shown in yellow. F, The individual binding sites in each DBL domain are 
structurally similar. Specifically, the sialic acid inserts into a valley at the interface of a helix and 
an extended loop present on both domains. The glycan coloring is the same as in E.  
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Figure 2. Sialic acid modeling and erythrocyte binding studies provide a detailed molecular 
description of the RII PfEBA-140 erythrocyte invasion interface. A, Close-up view of the F1 
binding pocket. Four residues directly contact the sialic acid. Hydrogen bonds are designated 
with black lines. B, Close-up view of the F2 binding pocket. Four residues directly contact the 
sialic acid. The single hydrogen bond interaction is shown with a black line. C, Erythrocyte 
binding by RII PfEBA-140 expressed on the surface of HEK-293 cells is sensitive to trypsin and 
neuraminidase treatment of red blood cells, but chymotrypsin resistant. Erythrocytes were treated 
with 0.1mg/mL trypsin, 0.1mg/mL chymotrypsin, or 5mU of Vibrio cholera neuraminidase at 
37ºC prior to the rosetting assay. Bound erythrocytes appear black around the transfected 
mammalian cells. The images are displayed at 20X magnification. D and E, RII PfEBA-140 
mutants were expressed on the surface of mammalian cells and tested for erythrocyte binding. 
GFP was used to assess proper expression of each construct. Wild type RII PfEBA-140 
extensively binds erythrocytes, and a construct containing GFP alone is not capable of binding. 
To identify critical binding interactions, individual glycan contact residues in the F1 and F2 
binding pockets were mutated to alanine or glutamate and tested for erythrocyte binding by 
rosetting assay. Bound erythrocytes appear black around the transfected mammalian cells. The 
images are displayed at 20X magnification. F and G, Percentage of cells expressing point 
mutants of RII PfEBA-140 that bind erythrocytes relative to wild type RII. The binding 
phenotypes are representative of the binding percentage quantified for 30 fields o f view per 
mutation. Lys347, mutated to alanine as a surface control residue, displays wild type binding.  
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Figure 3. RII PfEBA-140 glycan binding sites are distinct from other classes of sialic acid 
binding proteins. The PfEBA-140 F1 (orange) and F2 domains (blue) are shown overlayed with 
the A, TgMIC1 (light blue), B, Hemagglutinin (red), C, Selectin (purple), and D, Siglec (light 
green) sialic acid binding sites. The sialic acid molecule bound to PfEBA-140 is shown in green 
and the sialic acid bound to the protein of comparison is shown in grey. Arrows highlight 
structural differences in each case.  
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Figure 4. The F1 binding pocket surface is altered when Ile185 is mutated to valine in silico. A, 
The glycan binding surface containing Ile185 (the residue present in the construct used for 
crystallization) exhibits strong shape complimentary with the sialic acid. The overall surface is 
shown in grey on the top, the electrostatic surface is shown on the bottom (surface charge 
potential is colored from +3.5eV (blue) to -3.5eV (red)). The bound sialic acid is shown in green. 
B, The binding pocket surface is altered following in silico mutation of residue 185 to valine. 
The top displays the overall surface of the pocket in grey, and the bottom displays the 
electrostatic surface (surface charge potential is colored as in A). The altered surface cavity is 
identified with an arrow and the sialic acid is shown in green.  
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FIGURE 5. The sialyllactose bound structure illuminates a glycan induced structural change and 
allows for localization of putative sulfate-binding sites. A, Overlay of the sialyllactose bound (F1 
domain in orange, F2 domain in blue) and unbound (F1 domain in light orange, F2 domain in 
light blue) structures of RII PfEBA-140. The bound sialic acid molecules are shown in green. 
The glycan induced structural change is outlined in black. B, Close-up view of residues Thr493, 
Tyr494, and Leu495, which show a pronounced movement following glycan binding. C, The 
helix shift in the F2 domain observed upon glycan binding is propagated by sialic acid 
interference with main chain water molecule interactions. Glycan binding precludes access of 
two water molecules to the cavity indicated by the black arrow (the waters are present in the apo 
structure). In the absence of contacts mediated by these water molecules, the helix is 
destabilized, allowing the movement observed in the bound crystal structure. The water 
molecules are shown in cyan and the sialic acid in green. The bound F2 domain is shown in dark 
blue; the unbound F2 domain in light blue.  D, Three sulfate-binding motifs in RII PfEBA-140 
are adjacent to the sialic acid binding sites. Two other putative sulfate-binding motifs are distal 
to the binding sites. The putative sulfate-binding sites are shown in purple and identified with an 
arrow. 
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Figure 6. PfEBA-140 sialic acid recognition is distinct from that of PfEBA-175.Shown here is 
an overlay of the RII PfEBA-140 monomer with the dimer of RII PfEBA-175. The PfEBA-140 
F1domain is shown in orange and the F2 domain is shown in blue. The RII PfEBA-175 
monomer overlayed with RII PfEBA-140 is shown in light green. The second monomer of RII 
PfEBA-175 is shown in light purple. Residues of PfEBA-140 involved in sialic acid binding are 
shown in red. The sialic acid molecules bound to RII PfEBA-140 are shown in black for clarity. 
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Table 1: Data collection and refinement statistics 
 PfEBA-140 RII sialyllactose 
complex 
Data collection  
Space group P21 
Cell dimensions  
a, b, c (Å) 64.95, 76.03, 81.43 
    α, β, γ (º)  90.00, 96.93, 90.00 
Resolution (Å) 20-3.0 (3.09-3.0)  
Rmerge 7.8% (65.5%) 
I /σI 14.06 (2.05) 
Completeness (%) 96.2% (97.7%) 
Redundancy 3.00 (3.00) 
  
Refinement  
Resolution (Å) 20.0-3.0 
No. reflections 15,336 
Rwork / Rfree  (%) 21.82 / 25.48 
No. atoms  
    Protein 5,266 
    Ligand/ion 42 
    Water 22 
B-factors  
    Protein 87.18 
    Ligand/ion 64.23 
    Water 42.74 
r.m.s.d  
    Bond lengths (Å) 0.001 
    Bond angles (º) 0.437 
Ramachandran  
    Favored 95.52% 
    Allowed 4.48% 
    Disallowed 0.00% 
  
Values in parentheses are for highest-resolution shell. 
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Chapter 4  
 
PvDBP utilizes unique receptor binding interfaces and a 
novel two-step binding process to engage its RBC receptor
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4.1 Abstract 
Plasmodium parasites use specialized ligands which bind to red blood cell (RBC) receptors 
during invasion. Defining the mechanism of receptor recognition is essential for the design of 
interventions against malaria. Here, we present the structural basis for Duffy antigen (DARC) 
engagement by P. vivax Duffy binding protein (DBP). We used NMR to map the core region of 
the DARC ectodomain contacted by the receptor binding domain of DBP (DBP-RII) and solved 
two distinct crystal structures of DBP-RII bound to this core region of DARC. Isothermal 
titration calorimetry studies show these structures are part of a multi-step binding pathway, and 
individual point mutations of DARC contact residues result in a complete loss of RBC binding 
by DBP-RII. Two DBP-RII molecules sandwich either one or two DARC ectodomains, creating 
distinct heterotrimeric and heterotetrameric architectures. The DARC N-terminus forms an 
amphipathic helix upon DBP-RII binding. These structures of a Plasmodium ligand in complex 
with a red blood cell receptor define the molecular details of engagement for a pervasive class of 
ligands containing the Duffy binding-like fold. The studies reveal a receptor binding pocket in 
DBP and critical contacts in DARC, reveal novel targets for intervention, and suggest that 
targeting the critical DARC binding sites will lead to potent disruption of RBC engagement as 
complex assembly is dependent on DARC binding. These results allow for models to examine 
inter-species infection barriers, Plasmodium immune evasion mechanisms, P. knowlesi receptor-
ligand specificity, and mechanisms of naturally acquired P. vivax immunity. A step-wise binding 
model is proposed that may facilitate signaling through the transmembrane and cytoplasmic 
domains of DBP to activate pathways of invasion. It is anticipated that the structural basis of 
DBP host-cell engagement will enable development of rational therapeutics targeting this 
interaction.
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4.2 Author Summary 
Malaria parasites, including Plasmodium vivax, must actively invade erythrocytes during 
blood stage growth in humans. P. vivax Duffy Binding Protein (DBP) is a critical invasion ligand 
that recognizes the receptor Duffy antigen/Receptor for chemokines (DARC) during invasion. To 
identify critical binding contacts during parasite red blood cell invasion and determine the 
molecular basis of DBP receptor recognition, we identified the minimal region of DARC 
contacted by DBP and performed structural studies on the minimal binding domain of DBP in 
complex with the minimal region from DARC. These studies revealed that two DBP molecules 
bind two DARC molecules. We performed erythrocyte binding assays with binding site mutants 
and identified essential receptor contacts. The identification of receptor binding sites and 
molecular interactions critical to the invasion process provides a basis for targeted disruption of 
erythrocyte invasion mediated by DBP. The structural and functional studies of DBP and DARC 
presented here may aid in the rational design of vaccines and invasion inhibitory therapeutics. 
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4.3 Introduction 
Plasmodium vivax is a widely distributed human parasite, with 40% of the world’s 
population at risk of infection and an estimated 70-130 million cases of P. vivax malaria each 
year (Mendis et al., 2001, Price et al., 2007). P. vivax is prevalent in India, Southeast Asia, and 
South America (Mendis et al., 2001), but is rare in most of Sub-Saharan Africa (Welch et al., 
1977). This rarity is the result of a silencing mutation in the Duffy blood group, found at 
frequencies near fixation in Sub-Saharan Africa (Howes et al., 2011), that confers resistance to 
P. vivax (Miller et al., 1976). This phenotype has arisen independently at least three times, and P. 
vivax in malaria endemic regions has driven selection for the Duffy negative phenotype. This 
phenotype confers protection against P. vivax because during red blood cell (RBC) invasion the 
P. vivax Duffy Binding Protein (DBP) binds the Duffy antigen/receptor for chemokines (DARC) 
on RBCs (Wertheimer et al., 1989, Horuk et al., 1993). Therefore, RBCs which lack DARC are 
refractory to P. vivax invasion. DARC is an atypical GPCR, thought to serve as a ‘reservoir’ for 
excess inflammatory chemokines (Gardner et al., 2004).  
Repeated cycles of RBC invasion and rupture cause the clinical symptoms of malaria. To 
invade a RBC, Plasmodium merozoites release the contents of specialized apical organelles: the 
micronemes and rhoptries. DBP is a member of the erythrocyte binding-like (EBL) family of 
proteins, which localize to micronemes and use Duffy binding-like (DBL) domains to bind 
specific RBC receptors with high affinity. DBL domains are located in “region II” of EBL 
proteins (Chitnis et al., 1994, Tolia et al., 2005), and DBP region II (DBP-RII) is required for 
formation of a tight junction between Plasmodium and RBC membranes. DBP is an exceptional 
P. vivax therapeutic target because it is the sole EBL family member in the P. vivax genome 
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(Carlton et al., 2008). This contrasts with P. falciparum, which has multiple, redundant EBL 
family members which mediate RBC invasion by binding different host RBC receptors.   
DBP is a leading vaccine candidate against P. vivax malaria (Beeson et al., 2007). 
Individuals living in endemic regions develop natural immunity to P. vivax in an age-dependent 
manner which strongly correlates with humoral and cellular recognition of DBP-RII (Xainli et 
al., 2002, Xainli et al., 2003, Cole-Tobian et al., 2009). Antibodies against DBP inhibit P. vivax 
RBC invasion (Grimberg et al., 2007), and antibody epitopes in DBP-RII recognized by 
inhibitory antibodies have been identified (Chootong et al., 2010). However, due to a high level 
of polymorphism in DBP-RII and the selection for strain-specific immunity, identifying residues 
that are essential to the invasion interaction is still a critical step towards defining vaccination 
targets.  
Previous studies have illuminated key determinants of DBP-RII binding to DARC and begun 
to define essential elements of the binding interaction. DARC exists as two codominant alleles, 
Fya and Fyb, with a single polymorphism at residue 42. Fya contains a glycine, and Fyb an 
aspartate (G/D42) at this position. The Fyb phenotype has been shown to increase binding to 
DBP-RII (King et al., 2011). It is also known that DARC is sulfated on the erythrocyte surface at 
tyrosine residues 30 and 41, and sulfation of tyrosine 41 has been shown to play a role in binding 
to DBP (Choe et al., 2005). Specifically, a sulfated recombinant DARC N-terminus construct 
inhibits the DBP-RII erythrocyte interaction to a greater extent than an unsulfated construct. 
Extensive functional studies have also suggested interaction residues for both DBP-RII and 
DARC (Chitnis et al., 1996, Singh et al., 2003, VanBuskirk et al., 2004, Hans et al., 2005, 
Mayor et al., 2005, Tournamille et al., 2005). The crystal structure of DBP-RII has been solved 
(Batchelor et al., 2011), and illuminated a putative sulfotyrosine binding pocket. Biophysical 
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studies have demonstrated that a non-sulfated DARC construct functionally binds and is capable 
of inducing dimerization of DBP-RII (Batchelor et al., 2011), suggesting that regions outside of 
the sulfotyrosine residues play an important role in the binding interaction. Despite these studies 
on the DBP-RII interaction with DARC, the full mechanism of binding and complete extent of 
molecular interactions between these binding partners are not fully understood.  
In an effort to define the mechanism of DBP red blood cell binding and to identify specific 
molecular interactions at the P. vivax invasion interface, DBP-RII was crystallized with the 
DARC ectodomain. Two crystal forms were observed, a heterotrimeric complex in which one 
DARC molecule binds the DBP-RII dimer, and a heterotetrameric complex containing two 
DARC molecules bound to the DBP-RII dimer. The crystal structures of these two complexes 
represent the first structural characterization of a receptor-bound Plasmodium EBL ligand and 
provide insight into the structure of a portion of the DARC ectodomain that mediates this 
interaction. The structures illuminate DARC contact residues that explain inter-species barriers 
to P. vivax infection. In addition, point mutations in DARC binding site residues within P. 
knowlesi DBP homologs provide a potential model for the molecular basis of receptor specificity 
within the EBL family. The heterotetrameric complex shows that the DARC molecules are 
bound in parallel, resulting in a Plasmodium proximal face and a RBC proximal face of DBP-
RII. The structures confirm the previously identified DBP-RII dimer interface (Batchelor et al., 
2011) as a putative target of protective immunity, and reveal novel targets for naturally acquired 
immunity, including the RBC proximal face of DBP-RII and the DARC-binding pockets. Our 
studies also provide the basis for a framework defining the mechanism of DARC engagement by 
P. vivax. Specifically, the two bound forms of DBP-RII observed in the crystal structures suggest 
that an initial binding event followed by receptor-induced DBP dimerization leads to a 
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DBP:DARC heterotrimer that subsequently binds to a second DARC monomer to create the final 
heterotetrameric assembly. Isothermal titration calorimetry (ITC) experiments performed with 
recombinant DARC and DBP-RII support the two state, induced dimerization model of 
erythrocyte engagement.  
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4.4 Results 
DBP-RII engages the central region of the DARC N-terminal ectodomain 
DARC binds DBP-RII through its N-terminal 60 amino acid ectodomain (Horuk et al., 1993) 
and DARC binding induces dimerization of DBP-RII (Batchelor et al., 2011). Binding and 
dimer-induction in vitro has been demonstrated for non-tyrosine sulfated DARC N-terminal 
ectdomain (Batchelor et al., 2011). NMR experiments were performed to determine the region of 
an unsulfated version of the DARC N-terminal ectodomain contacted by DBP-RII (Fig. 1). 
Resonance assignments for the 60 N-terminal amino acids of DARC (DARC 1-60) were 
obtained by standard triple resonance experiments. The peaks are not well dispersed (Fig. 1) and 
chemical shifts closely match canonical random coil chemical shifts, consistent with a lack of 
secondary structure.  
In the presence of DBP-RII, the large size of the 88 kDa DBP-RII:DARC 1-60 complex led 
to significant broadening of many peaks, preventing full assignment. However, comparison of 
the spectra between bound and unbound states revealed that signals corresponding to the first N-
terminal 15-16 amino acids overlay well and have only modest line broadening. This result 
suggests that this region remained unstructured upon binding and does not directly contact DBP-
RII.  At the C-terminus, residues from 44-60 exhibit some line broadening or chemical shift 
changes, but this region, similar to that of the N-terminus, was still relatively unperturbed upon 
binding to DBP-RII. In contrast, peaks corresponding to the central region of DARC1-60 became 
significantly broadened, shifted, or disappeared in the bound complex. These results indicate that 
residues within the central region of the DARC ectodomain are highly perturbed upon interaction 
with DBP-RII and are thus most likely to directly contact DBP and form the minimal binding 
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domain. This result is consistent with a region from DARC sufficient for blocking RBC binding 
by DBP-RII (Chitnis et al., 1996).  
The DARC ectodomain forms a helix that binds the dimer interface of DBP-RII 
Screening for crystallization conditions of DBP-RII in complex with DARC ectodomain 
constructs designed around the central binding region resulted in two crystal structures of the 
DBP-RII:DARC complex. The first was a 1.95Å crystal structure of a 2:1 complex of DBP-
RII:DARC16-43 (Table 1). In this structure, two DBP-RIIs (DBP1 and DBP2) bind a single 
DARC (DARC A) creating the heterotrimer (Fig. 2A) with a total buried surface area of 2241.8 
Å
2
. The second structure was a 2:2 complex of DBP-RII:DARC14-43 that was refined to 2.6Å 
(Table 1). In the second structure, two DBP-RIIs each bind two DARCs (DARC A and DARC 
B) creating two DARC binding sites. This architecture creates a heterotetramer (Fig. 2B), with a 
total buried surface area of 3628.6 Å
2
. We postulated that the two structures represent snapshots 
in the assembly of the DBP-RII:DARC complex and may define structural changes during step-
wise binding. Additionally, in the heterotrimer, the second DARC binding site is preformed to 
accept another DARC. In both crystal forms the two DBP-RII molecules are not identical and no 
higher order symmetry exists in the asymmetric unit. Therefore, DARC binding results in two 
distinct DBP-RII molecules in each asymmetric unit. 
DBP-RII interacts with DARC in a step-wise binding process  
We utilized ITC to examine the mechanism of DBP-RII:DARC engagement and assembly in 
solution. ITC is an excellent technique to unambiguously determine interaction stoichiometries 
and can be applied to examine step-wise and multi-state binding systems in solution. Titration of 
DARC1-60 into DBP-RII demonstrated that DARC binding occurs in a step wise assembly 
consistent with the crystallographic studies. A biphasic binding isotherm indicative of a two-state 
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assembly was observed (Fig.3). The first binding event has a molar ratio of 0.5, expressed in 
monomers of DBP-RII, indicative of a 2:1 heterotrimeric complex of (DBP-RII)2:(DARC1-60)1. 
The second binding event occurs at a molar ratio of 1 indicative of a 2:2 heterotetrameric 
complex or (DBP-RII)2:(DARC1-60)2. The data were fit to a two independent site binding model 
which suggested affinities of  2151±352nM for the first binding event and  56.8±50.4nM for the 
second binding event, consistent with high affinity binding. However, it should be noted that the 
two independent site binding model is not a perfect description of DBP-RII:DARC binding as 
receptor-induced dimerization is not included in the model. Therefore, exact affinity 
determination will require further work necessary to define all thermodynamic parameters of 
binding. While the exact affinity will require a more detailed fitting model, the stoichiometries 
determined and thus the observation of step-wise assembly in solution are not affected by the 
fitting model selected and are reliable. In summary, the crystallographic and ITC solution data 
presented here demonstrate a multi-step sequential binding mechanism involving DARC-induced 
assembly of DBP-RII. 
Identification of molecular interactions between DARC and DBP-RII 
The NMR studies indicate DARC1-60 lacking three cysteines is unstructured in the absence 
of DBP-RII. In both structures, clear density is seen for DARC residues 19-30 (Fig. S1). DARC 
is induced to form an amphipathic helix in the crystal structures upon binding and engages a 
positively charged groove at the DBP-RII dimer interface (Fig. S1). All DARC interacting 
residues and the dimer interface of DBP-RII are located in subdomain 2 of DBP-RII. In addition 
to the dimer interface, each DARC binding site, one in the heterotrimer and two in the 
heterotetramer, can be broken into two interfaces: a primary DARC binding interface with one 
DBP-RII monomer, and a secondary DARC binding interface created by the second DBP-RII 
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monomer (Fig. 4 and 5, Table 2 and 3). The DBP-RII homodimer interface is composed of 
DBP1 residues I265-R274 and DBP2 residues F261-Y278 in the heterotrimer (Fig. 4C), and 
DBP1 residues H262-R274 and DBP2 residues F261-Y278 in the heterotetramer (Fig. 5B). The 
primary DARC binding interface in both structures consists of DBP-RII residues L270-K289 of 
helix 4 and Q356-K367 of helix 7 (Fig. 4 and 5). DBP-RII binds the amphipathic DARC helices 
through a hydrophobic core flanked by electrostatic interactions.  
The secondary DARC binding interface is formed by residues V254 to F267 (loop 254-267) 
(Fig. 4B, 5C-D). When DBP-RII is not bound to DARC this region is disordered (Batchelor et 
al., 2011).  Loop 254-267 contains residues which are required for binding (VanBuskirk et al., 
2004), and are recognized by neutralizing antibodies (Chootong et al., 2010). When DARC is 
bound, loop 254-267 becomes ordered and engages the DARC bound by the primary interface of 
a neighboring DBP-RII. In the heterotrimer, residues H262-T266 make contacts at the secondary 
interface (Fig. 4B). In the heterotetramer, DBP1 residues R263-I265 and DBP2 residues F261-
D264 contact DARC of the opposing monomer (Fig. 5C-D). Thus, DARC is sandwiched 
between two DBP-RII molecules in each DARC binding site. 
Architectural transitions upon receptor binding 
In the absence of receptor, DBP-RII crystallized as a dimer stabilized by phosphates 
(Batchelor et al., 2011). Although this prior structure resembles the receptor-bound conformation 
presented here, there are substantial structural differences in the architecture of the dimer 
compared to the heterotrimer or heterotetramer. These differences are crucial towards correctly 
defining the invasion interaction. In the heterotrimer structure, a new DBP-RII homodimer 
interface is created by a translation of 7 residues covering 12Å along helix 4, relative to the 
unbound structure (Fig. S2A). The heterotetramer structure has a larger translation along the 
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same interface in the same direction, with a second 12 Å displacement relative to the 
heterotrimer (Fig. S2B), and a 23 Å displacement relative to the unbound DBP-RII homodimer 
interface (Fig. S2C). The directionality of these transitions is consistent with sequential steps in a 
stepwise mechanism of receptor binding. While there are major changes in the DBP-RII:DARC 
complex architectures, individually each DBL domain aligns well to the DBP-RII DBLs solved 
in the absence of receptor (Fig. S2D-G). 
Critical contacts in DARC 
The observation that DARC 19-30 is contacted by DBP-RII is consistent with alanine 
scanning work (Tournamille et al., 2005). Mutation of DARC residues 20-22 and 24-26 
abrogated binding in a direct protein interaction assay. Each of these residues, with the exception 
of D21, makes direct contacts with DBP-RII and are buried in the complex (Fig. 4 and 5). D21, 
which is required for DBP-RII binding but does not directly contact DBP-RII, stabilizes the 
DARC N-terminal helix dipole by positioning its acidic side chain directly over the helix. E23, 
on the other hand, is on the surface of the complex and is solvent exposed. Mutation of E23 to 
alanine had no effect on binding consistent with its location in the complex. 
Sulfotyrosine residues in DARC increase DARC’s ability to inhibit DBP-RII RBC binding 
(Choe et al., 2005). A previous structure of DBP-RII alone identified a potential sulfotyrosine 
binding site that includes residues K273 and Q356 (Batchelor et al., 2011). In the receptor-bound 
structure presented here, the hydroxyl of DARC Y30 points directly at this pocket created by 
K273, and Q356 (Fig. S3). Therefore, sulfotyrosine 30 appears to bind at this site when DARC is 
sulfated. DARC residues 14-43 were included in our crystallographic studies. However, clear 
density was only observed for residues Q19 to Y30, and no density was present for the remainder 
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of DARC. The crystallographic data along with the RBC binding studies discussed above 
support that residues 19-30 constitute a critical interaction site with DBP-RII. 
Residues in DBP-RII that contact DARC are required for RBC engagement 
Having identified residues of DBP-RII that directly contact DARC, structure-guided 
mutagenesis was used to determine whether this model of binding explains DBP engagement of 
RBCs (Fig. 6). Mutation of residues Y363 or A281 in the primary DARC binding interface led to 
a complete loss of binding in a functional RBC binding assay. This is expected as DARC binding 
drives complex formation and mutations preventing DARC binding will completely abrogate 
complex formation and attachment. These results are consistent with previous mutational studies 
that identified potential interaction residues between DBP-RII and DARC (VanBuskirk et al., 
2004, Hans et al., 2005), several of which map to the interaction surfaces identified here. 
Residues D264, I265 and T266 are located in the secondary DARC binding interface and directly 
contact DARC. Mutation of these residues resulted in a loss in RBC binding, demonstrating that 
the secondary DARC binding interface plays a role in engaging DARC during RBC invasion. 
Large bulky amino acid changes are required in order to disrupt binding by mutation at the 
secondary binding site, as is expected from the large contact area created by the additional 
interfaces in the full complex. The need for large changes is consistent with a lack of an effect on 
binding when mutations to alanine or conservative changes were introduced at these residues 
(VanBuskirk et al., 2004, Sampath et al., 2013). Together, these results support the functional 
role of both DARC binding interfaces. 
DARC on erythrocytes is sulfated (Choe et al., 2005). The mutational studies discussed 
above show that sulfation of DARC on erythrocytes, and the remaining segments of full length 
DARC, cannot compensate for the loss of the critical binding sites containing L270-K289 and 
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Q356-K367 that bind DARC 19-30. In particular, recombinant DBP-RII containing Y363A is 
unable to bind to sulfated DARC in vitro (Hans et al., 2005). This result also demonstrates that 
sulfation of DARC cannot compensate for the loss of the DARC binding sites induced by the 
Y363A mutation. Together, the results identify essential binding residues within DBP-RII, 
consistent with prior studies, which form critical binding sites required for engagement of 
DARC. 
DBP receptor specificity is manifested through changes in the DARC binding sites 
P. knowlesi uses three different DBP homologs to invade human and rhesus macaque RBCs 
(Chitnis et al., 1994). Only P. knowlesi DBPα (PkDBPα) binds DARC, while PkDBPβ and 
PkDBPγ do not bind human RBCs and recognize a receptor other than DARC (Chitnis et al., 
1994). This receptor specificity is likely due to three amino acid changes in the critical DARC 
binding site of DBP that are changed to non-conservative amino acids in PkDBPβ and/or 
PkDBPγ (Fig. 6C). The DBP residue with the most extensive DARC contacts is Y363. In both 
PkDBPβ and PkDBPγ, Y363 is changed to leucine. Mutation of Y363L resulted in a complete 
loss of binding (Fig. 6D and E) consistent with a role for this residue in receptor specificity. 
Additionally, R274E and Q356Y in PkDBPβ, as well as Q356D in PkDBPγ, would likely 
destabilize DARC binding as both R274 and Q356 contact the DARC residues E23 and Y30, 
respectively. It has been demonstrated that a R274E mutation in DBP-RII completely prevents 
RBC binding (Batchelor et al., 2011). Mutation of Q356D and Q356Y resulted in a loss in RBC 
binding, with Q356D having a large effect (Fig. 6D and E). Thus, contacts identified in the 
DBP:DARC structure provide insight into why PkDBPβ or PkDBPγ do not bind DARC on 
human RBCs.
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4.5 Discussion 
Numerous functional and immunological studies have been conducted on the P. vivax DBP 
invasion system since the Duffy antigen was found to be essential to this species in the 1970’s 
(Miller et al., 1976). Here we have shown using crystallography that DBP-RII binds DARC 
forming a heterotrimer and heterotetramer and demonstrated using ITC that the interaction 
assembles in discrete steps. In addition, we identify DARC residues 19-30 as a critical 
interaction site for DBP-RII binding, and thus to tight junction formation during invasion. These 
studies also identify DBP-RII residues that directly contact the DARC receptor, including L270-
K289, Q356-K367 and F261-T266. The structural and mechanistic basis of Duffy recognition by 
P. vivax provides a context for prior work and may assist with the rational design of therapeutics 
and vaccines targeting this essential P. vivax binding interaction. 
The binding pockets in DBP identified here are distinct from a patch of residues previously 
suggested to engage DARC (Singh et al., 2006) (Fig S4). These residues were proposed based on 
loss of binding of DBP to DARC upon mutation; however, no data for direct interaction of this 
patch of residues with DARC was presented. In contrast, the crystal structure of P. vivax DBP in 
complex with DARC demonstrates clear contact points between the two binding partners, and 
mutagenesis data strongly supports the critical role of the residues identified in the binding 
pockets. 
Phylogenetic studies have identified primate DARC residues under positive selection to 
block Plasmodium infection (Demogines et al., 2012). V25 in DARC is especially polymorphic 
among primates and under strong positive selection. This is because DBP makes essential 
hydrophobic packing interactions with V25 (Fig. 7A), disruption of which would strongly 
destabilize binding. Gorillas, the ancient host of P. falciparum (Liu et al., 2010), have a V25A 
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mutation in DARC. This disrupts hydrophobic interactions, prevents DBP binding (Tournamille 
et al., 2005), and serves as an inter-species barrier to P. vivax infection. 
Sequencing of parasite populations show particular sites of DBP are under strong positive 
selective pressure to evade the immune response (Xainli et al., 2000, Gosi et al., 2008, Nobrega 
de Sousa et al., 2011). Many polymorphic DBP residues are located far from the DARC binding 
sites (Fig. 7B) (VanBuskirk et al., 2004, Hans et al., 2005). The most polymorphic region of 
DBP, the DEK epitope, forms a ridge directly opposite DARC, flanking the secondary binding 
interface and homodimer interface. Converting this epitope to small, nonpolar amino acids, 
focuses the immune response towards cross-specific neutralizing epitopes (Ntumngia et al., 
2012). Our results suggest that this hypervariant DEK epitope does not play a direct role in 
DARC binding. Polymorphisms in the DEK epitope should not affect DBP function, but could 
interfere with immune recognition of DBP. Antibody recognition of the hypervariant DEK 
epitope may neutralize P. vivax by preventing assembly of the DBP-RII:DARC complex, and 
thus sterically preventing DBP-RII homodimeric contacts.  Polymorphisms are heavily selected 
for within the DEK epitope suggesting P. vivax evades this potentially neutralizing antibody 
response by antigenic variation within these residues.  
The studies presented here define a putative mechanism for known neutralizing epitopes of 
P. vivax DBP-RII and illuminate potential new targets for naturally acquired immunity. 
Specifically, both DARC helices are oriented in a parallel manner (Fig. 2B and 2D), and DARC 
itself is a homodimeric GPCR. Because only 30 amino acids, DARC residues G31 to S60, 
separate the structure from the RBC membrane, the surface of the DBP-RII dimer with DARC 
Y30 is proximal to the RBC membrane, and the alternate surface faces the Plasmodium 
membrane. Antibody recognition of DBP-RII’s RBC proximal surface prior to DARC binding 
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neutralizes DBP by sterically preventing DBP-RII from approaching the RBC surface. This 
model is confirmed by recent work which identified several DBP neutralizing epitopes 
recognized by human antibodies from individuals living in endemic areas (Chootong et al., 
2010) which are located either directly at the DARC binding sites or at DBP-RII’s RBC 
proximal surface (Fig. 7C). In addition, the most potent known neutralizing epitope for DBP 
includes much of helix 4 and loop 254-267 (Chootong et al., 2010), which contains the DBP-RII 
dimerization interface and the DARC binding sites. Disrupting DBP-RII dimerization would 
both destabilize DARC binding by preventing secondary DBP-RII contacts and destroying 
interaction contributions due to avidity. Recently, mouse monoclonal antibodies that bound 
subdomain 3 of DBP-RII also blocked binding to erythrocytes (Siddiqui et al., 2012). Subdomain 
3 lies in close proximity to the RBC surface (Fig. 8) and these antibodies may block binding by 
preventing DBP-RII from approaching the RBC surface and contacting DARC. The 
identification of two DARC binding sites within DBP-RII and the structural orientation of each 
molecule provide insight into the mechanisms of antibody inhibition of P. vivax RBC invasion. It 
appears that antibodies targeting DBP-RII are capable of preventing DARC binding by 
recognizing DBP-RII’s RBC proximal surface, DARC recognition sites, or the homodimeric 
interface, and may block invasion using other, currently unidentified mechanisms.  
The crystallographic and ITC solution studies presented here support a step-wise binding 
model in which receptor-induced DBP-RII dimerization facilitates formation of a heterotrimer 
that subsequently recruits a second DARC molecule to form a heterotetramer (Fig. 8). Due to 
avidity contributions to binding inherent in a two-site mechanism, this heterotetrameric complex 
may enable the observed tight binding of P. vivax to the RBC membrane. Since DBP-RII is 
monomeric in the absence of DARC (Batchelor et al., 2011), the dimer interface and DARC 
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binding pockets are exposed and accessible to antibodies prior to DARC engagement. DARC is 
known to exist as a homodimeric and heterodimeric GPCR (Chakera et al., 2008). The 
heterotrimer and heterotetramer could represent DBP-RII binding to a DARC heterodimer or 
homodimer, respectively. The observed transitions may be a selectivity mechanism for DBP-RII 
to preferentially bind homodimeric DARC while maintaining the ability to bind to a DARC 
heterodimer. The binding model proposed here is applicable to other DBL domain proteins that 
may oligomerize upon receptor binding (Tolia et al., 2005, Batchelor et al., 2011, Hodder et al., 
2012, Lin et al., 2012, Malpede et al., 2013). Since dimerization is prevalent in receptor 
signaling, it is plausible that complex assembly initiates a signal through the transmembrane and 
cytoplasmic domains of DBP to activate pathways of invasion.  
Although structure determination of the DBP-RII:DARC complexes allows for visualization 
and identification of critical contact points, the relevance of each intermediate to complex 
assembly in solution is not immediately known from the static pictures of binding. To begin to 
assess the biological role of complex assembly, we utilized ITC to demonstrate that two binding 
events corresponding to the formation of a heterotrimer and heterotetramer exist in solution. We 
further tested mutant DBP-RII constructs for RBC binding and demonstrated that these 
mutations ablate binding to RBCs, supporting the biological role of the DARC contacts 
identified here as well as the role of the dimer interface. In addition, the large buried surface area 
for both DARC binding sites and the ITC measurements suggest high affinity interactions. This 
study thus unambiguously identifies DARC residues 19-30 as a critical binding element that 
interacts with DBP residues L270-K289, Q356-K367 and F261-T266. 
The biphasic profile obtained by ITC is different from studies previously reported where a 
single binding event with a molar ratio of 1 was observed indicative of the heterotetramer 
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(Batchelor et al., 2011). This difference is likely due to the buffer conditions used in each case. 
In prior studies, titrations were performed at a salt concentration of 50 mM while the studies 
presented here were performed in PBS to examine binding under physiological conditions. These 
results suggest that observation of the heterotrimer intermediary step by ITC is salt dependent. 
Never-the-less, the biphasic profile and step wise binding mechanism presented here are 
representative of the assembly mechanism under physiologically relevant conditions.  
In both crystal structures, clear electron density was observed for residues 19-30 of DARC. 
Mutational studies (VanBuskirk et al., 2004, Hans et al., 2005) and glycan shielding experiments 
(Sampath et al., 2013) have identified several patches of residues that affect binding of DBP to 
RBCs, some of which overlap and are consistent with the DARC contacts identified here. There 
are additional residues outside the DARC binding pockets that when altered reduce binding 
(VanBuskirk et al., 2004, Hans et al., 2005, Sampath et al., 2013). Therefore, the complete range 
of interactions between DARC and DBP-RII will likely include additional patches of residues in 
DBP. Specifically, sulfation of tyrosine 41 and the Fya/Fyb polymorphism have been shown to 
play a role in binding (Choe et al., 2005, King et al., 2011). However, the specific mechanism by 
which these changes impact binding is unknown. In addition, an association between the N-
terminus and additional extracellular loops of DARC has been suggested to play a role in 
chemokine binding to DARC (Tournamille et al., 1997).  Further studies are necessary to fully 
understand the role of tyrosine sulfation, the Fya/Fyb polymorphism, and the potential role of 
additional regions and loops of DARC during P. vivax binding and RBC invasion.  
The identification of critical DARC binding pockets presented in this study may facilitate the 
rational design of therapeutics that seek to inhibit RBC binding. Small molecule inhibitors that 
bind to the DARC binding pocket and prevent DARC engagement could disrupt merozoite 
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invasion, and thus P. vivax growth. Alternately, disruption of complex assembly by small 
molecules, as has been described for AMA-1:RON-2 (Srinivasan et al., 2013), or antibodies 
would also provide novel methods for preventing RBC invasion. Since complex assembly is 
dependent on DARC binding, the most potent disruption of RBC engagement is expected by 
targeting DARC binding sites. Recent work examining the mechanism of monoclonal antibodies 
targeting EBL ligands supports the view that targeting receptor binding sites and multimerization 
interfaces of EBL ligands effectively prevents RBC binding and limits parasite growth in vitro 
(Chen et al., 2013). Additionally, glycan masking experiments with DBP-RII identified the 
dimer interface and surfaces adjacent to this interface as critical binding sites and targets of an 
inhibitory antibody response (Sampath et al., 2013).  This result supports the importance of 
identifying and targeting essential functional residues/interfaces of DBP-RII and confirms the 
biological importance of the contact points identified in this study.  
This work also has implications for diagnostics and measures aiming to quantify the immune 
response to natural infection and in determining the efficacy of vaccine candidates. For a more 
robust measure of protection, these approaches should quantify the immune response to the 
functional regions identified here in addition to the response to the entire DBP-RII DBL domain.  
This study thus expands our understanding of the essential interaction between DBP and DARC 
and may aid in defining in vivo studies that seek to examine the extensive receptor-ligand 
binding interactions that are essential to RBC invasion by Plasmodium species. 
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4.6 Experimental Procedures 
Protein Expression, Purification, and Complex Formation 
DBP-RII and DARC were produced as previously described (Batchelor et al., 2011). DARC 
constructs were expressed in E. coli with an N-terminal GB1 tag, followed by a hexahistidine tag 
and a PreScission Protease cleavage site. Nickel-NTA chromatography followed by PreScission 
protease treatment and gel filtration resulted in a homogenous sample.  
NMR 
NMR data were collected at 298 K on a 600 MHz Bruker spectrometer equipped with a 
triple-resonance room temperature probe and a QCI cryoprobe. Backbone assignments for the 
non-proline residues in DARC 1-60 were obtained using standard HNCACB, CBCA(CO)NH,  
HN(CA)CO, and HNCO experiments. Once the DARC1-60 backbone resonances had been 
assigned, we collected 1H-15N-TROSY spectra of DARC1-60 in the presence of DBP-RII. As 
DARC residues tightly bound to DBP-RII in a large complex are not visible, peaks which remain 
in the DBP-RII:DARC 2D 1H-15N TROSY and 3D TROSY triple resonance spectra revealed 
residues which are not bound by DBP-RII.  
Crystallization and Data Collection 
Before complex formation, DBP-RII and DARC were purified separately by size-exclusion 
chromatography to remove any trace aggregates in either sample. The DBP-RII:DARC 
complexes were prepared by mixing purified DBP-RII and purified DARC in 1:1.2 molar ratio. 
The DBP-RII:DARC complexes were purified using size-exclusion chromatography in 20 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, and 50 mM sodium 
chloride. These sample was then concentrated in an Amicon concentrator with a 3-kDa 
molecular weight cutoff to 20mg ml
-1
 for crystallization trials. 
108 
 
Native DBP-RII:DARC crystals of both constructs were grown by hanging-drop vapor 
diffusion by mixing 1 μl of protein solution at 20 mg ml-1 and 1 μl of reservoir solution 
containing 0.1 M HEPES pH 7.4 and 20% (w/v) polyethylene glycol 6000. Crystallization of 
DBP-RII in complex with DARC 16-43 yielded the heterotrimeric structures, while 
crystallization of DBP-RII in complex with DARC 14-43 yielded the heterotetrameric crystals. 
The different crystal forms are not due to the DARC constructs used, rather serendipitous 
formation of one or either of the stable states upon complex assembly. Crystals were 
cryoprotected by transfer to reservoir solutions supplemented with glycerol and flash frozen in 
liquid nitrogen. Data for the heterotetramer was collected at a wavelength of 1.0 Å at beamline 
4.2.2 of the Advanced Light Source, Lawrence Berkeley National Laboratory. Data for the 
heterotrimer was collected at a wavelength of 0.97929 Å at beamline 19-ID of the Advanced 
Photon Source, Argonne National Laboratory. Data reduction and processing was performed in 
XDS (Kabsch, 2010). Data collection statistics are shown in Table 1. 
Structure Solution 
Both structures were solved by molecular replacement using DBP-RII apo-structure 
(Batchelor et al., 2011) leading to a starting model with Rwork/Rfree of 37.3%/38.1% for the 
heterotrimer and an Rwork/Rfree of 30.0%/30.1% for the heterotetramer. NCS restraints were 
not imposed on the two copies of DBP-RII during refinement as it was clear from electron 
density maps they were not identical. Subsequent automated rebuilding in PHENIX 
AutoBuild(Adams et al., 2010), manual rebuilding in COOT0.7 (Emsley et al., 2010)  and 
refinement in PHENIX1.7.3 (Adams et al., 2010)lead to a final model with Rwork/Rfree of 
16.62%/20.47% for the heterotrimerand 18.29%/23.28% for the heterotetramer(Table 1). These 
low R factors combined with the good Ramachandran plot statistics analyzed by MolProbity 
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(Davis et al., 2007) indicated that structure refinement was complete. Residue distributions in the 
Ramachandran plot for the heterotrimer were 98.42 % allowed, 1.58 % additionally allowed and 
0 % disallowed. Residue distributions in the Ramachandran plot for the heterotetramer were 
95.72 % allowed, 4.28 % additionally allowed and 0 % disallowed. The atomic coordinates and 
structure factors for the structure have been deposited in the protein data bank with accession 
numbers 4NUV and 4NUU. 
Isothermal Titration Calorimetry 
DBP-RII was prepared as described above, with the addition of an ion-exchange 
chromatography step prior to ITC measurements. DBP-RII and DARC1-60 were exchanged into 
PBS to ensure measurements were made under physiological conditions. ITC experiments were 
carried out at 10°C using a VP-ITC instrument (MicroCal). DARC1-60 at 1.3 mM was titrated 
into 1.4 mL of 130 μM DBP-RII. Traces were analyzed using Origin Version 5.0 (MicroCal). 
Stoichiometry and binding constants were calculated by fitting the integrated data to an 
independent two-site binding model. Protein concentrations were determined by absorbance 
measurements under denaturing conditions (6 M guanidinium hydrochloride, 10 mM 
dithiothreitol). 
Functional Studies 
DBP-RII with a C-terminally fused green fluorescent protein (GFP) was cloned into plasmid 
pRE4 for surface expression in mammalian cells. Single-amino-acid mutations were introduced 
in DBP-RII using the QuickChange method (Stratagene). Fresh monolayers of HEK293T cells 
were cultured in 3.5-cm-diameter wells and transfected with 2 µg ml
-1
 DNA in 
polyethyleneimine. The binding assay was performed 20 h after transfection. Anonymized 
human RBCs (ZenBio) were added to each well in a 10% suspension, incubated at 37 °C for 1 h, 
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and washed three times with PBS. Binding was quantified by counting rosettes observed over ten 
fields of view at x200 magnification. Transfected HEK 293T cells with five or more attached 
RBCs were defined as positive rosettes. In each experiment, three wells of HEK 293T cells were 
transfected for each mutation. Cell counting was performed using ImageJ (NIH) on randomized 
images. Three fields of view from ten independent transfections (final n = 30) were counted for 
each sample (wild type or mutant). Significance was tested by a paired two-tailed Student's t-test 
as the data were normally distributed and had large sample sizes (n = 30). 
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4.7 Figures and Tables 
 
 
 
 
Figure 1: Residues 14-43 of DARC contain the minimal binding region. 
1
H-
15
N-TROSY spectra 
of unbound DARC 1-60 (black) overlaid on 
1
H-
15
N-TROSY spectra of DARC 1-60 in the 
presence of excess unlabelled DBP-RII (red). Sequence assignments are shown for the unbound 
DARC 
1
H-
15
N-TROSY spectra. Peaks still visible in the presence of DBP-RII (red) are at DARC 
1-60's N- and C- termini. Residues that disappear in the presence of DBP-RII are in the center of 
DARC and delineate the binding region. 
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Figure 2: Crystal Structure of the DBP-RII:DARC heterotrimer and heterotetramer. Overview of 
(A) and DBP-RII:DARC heterotrimer and (B) the DBP-RII:DARC heterotetramer. Rotated 
views, (C) and (D), show DARC helices are oriented in parallel in the heterotetramer. DBP-RII 
monomers are in yellow and green. DARC monomers are in purple and blue. 
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Figure 3: Isothermal titration calorimetry reveals step-wise binding of DARC to DBP-RII in 
solution. (A) A biphasic binding profile is observed indicating the formation of the heterotrimer 
at a molar ratio of 0.5 (n = 0.45±0.03,Kd1 = 2151±352 nM, ΔH1 = -2725±153 cal/mol) and 
heterotetramer at a molar ratio of 1 (n = 0.48 ±0.04, Kd2 = 56.8±50.4 nM, ΔH1 = -3339±57 
cal/mol). Molar ratios are expressed as monomers of DBP-RII. Open circles denote unbound 
DBP, closed circles denote bound DBP. Titration of (B) PBS into DBP and (C) DARC into PBS 
reveals no observable profiles demonstrating the biphasic profile is due to DARC binding to 
DBP. In all cases, the top panel contains raw binding data, and the bottom panel changes in 
enthalpy associated with binding. 
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Figure 4: Binding interfaces of the DBP-RII:DARC heterotrimer. (A) Global view of the DBP-
RII:DARC heterotrimer, showing (B) DARC monomer A interactions and (C) the DBP-RII 
homodimeric interface. DARC monomer A is in purple, DBP-RII monomer 1 is in green and 
DBP-RII monomer 2 is in yellow. Residue numbers are labeled and DARC residue labels are 
underlined. 
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Figure 5: Binding interfaces of the DBP-RII:DARC heterotetramer. (A) Global view of the 
DBP-RII:DARC heterotetramer, showing (B) the DBP-RII homodimeric interface, (C) DARC 
monomer A interactions, and (D) DARC monomer B interactions. DARC monomer A is in 
purple, DARC monomer B is in blue, DBP-RII monomer 1 is in green and DBP-RII monomer 2 
is in yellow. Residue numbers are labeled and DARC residue labels are underlined. 
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Figure 6: The structural studies define red blood cell binding. (A) Adherent HEK293 cells in 
grey bind to darker, smaller red blood cells when transfected with a DBP-RII surface expression 
plasmid with a GFP marker. Red blood cell rosetting images for DBP-RII mutants, showing 
bright field (left), GFP (center), and merged images (right). (B) Percentage of cells expressing 
point mutants which bind red blood cells, relative to wildtype, shown with standard error. (C) 
The major DBP-RII:DARC residues identified in the crystal structures are indicated by red dots. 
Non-conservative P. knowlesi mutations at critical DBP-RII:DARC contact residues 274, 356, 
and 363 suggest why PkDBPα but not PkDBPβ or PkDBPγ bind DARC. (D) Red blood cell 
rosetting images for DBP-RII receptor specificity mutants, showing bright field (left), GFP 
(center), and merged images (right). (E) Percentage of cells expressing receptor specificity point 
mutants which bind red blood cells, relative to wildtype, shown with standard error. 
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Figure 7: Mapping polymorphic residues and inhibitory epitopes reveals targets of selective 
pressure. DBP-RII molecules are in green and yellow. DARC molecules are in purple and blue. 
DARC residue labels are underlined. (A) Nonsynonymous DARC polymorphisms in primates, 
blue, which make critical contacts with DBP-RII provide a mechanism for inter-species 
transmission barriers. (B) Polymorphic DBP residues, in blue, are spread throughout the 
molecule. The most polymorphic region of DBP is the “DEK epitope” opposite the DARC14-43 
binding site. (C) Inhibitory epitopes, in red and brown, map to the heterotetramer interface, 
DARC binding pockets and RBC proximal face of DBP-RII.  
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Figure 8: A model for attachment during invasion. An initial binding event is followed by 
receptor-induced dimerization, as in the DBP-RII:DARCheterotrimer. This brings a second 
DBP-RII molecule in close proximity to a second DARC ectodomain in the DARC homodimer. 
A second binding event creates the DBP-RII:DARCheterotetramer. DBP-RII molecules are in 
green and yellow and DARC19-30 molecules are in purple and blue. The DARC homodimer is 
represented by a homology model. A schematic for the stepwise assembly is show at the bottom. 
Closed circle – bound DBP-RII, open circle – unbound DBP-RII. 
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Figure S1: DARC residues 19-30 are contacted by DBP-RII. DARC19-30 binds to a positively 
charged groove at the DBP-RII dimer interface of both (A) the DBP-RII:DARC heterotrimer and 
(B)  the DBP-RII:DARC heterotetramer. Electrostatic potential is shown from -7.5 to 7.5 kT/e 
with positive potential in blue and negative potential in red.  2fo-fc electron density maps, 
contoured at 1σ clearly show the presence of (C) a single DARC19-30 in the heterotrimer and 
both (D) DARC19-30A and (E) DARC19-30B in the two DBP-RII binding sites of the 
heterotetramer. DARC monomers are in purple and blue and DBP-RII monomers are in green 
and yellow.   
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Figure S2: Upon receptor binding, new regions of DBP-RII become structured, while 
preexisting structural regions undergo no major conformational changes. During the transition 
from the heterotrimeric to heterotetrameric complex, a change in the overall architecture of the 
DBP-RII dimer is observed. In (A-C) the DARC-bound DBP-RII heterotetramer is green and 
yellow, the DARC-bound DBP-RII heterotrimer is light green and light yellow, and unbound 
DBP-RII is dark green and orange. Structural transitions in each case are designated with an 
arrow as well as with the distance of the structural shift. (A) A translation covering 12 Å along 
helix 4 defines the difference between the heterotrimeric structure and a prior structure of DBP-
RII in the absence of receptor. (B) A translation covering 12 Å across helix 4 is the difference 
between the heterotrimeric structure and the heterotetrameric structure. (C) A translation 
covering 23 Å along helix 4 is the difference between the heterotetrameric structure and DBP-
RII in the absence of receptor, which defines the full shift following binding of both DARC 
molecules. (D-G) Alignments of the individual monomers of the DBP-RII:DARC heterotetramer 
and unbound DBP-RII. (D) Monomer A of the heterotetramer (green) with monomer A unbound 
(dark green), (E) monomer A of the heterotetramer (green) with monomer B (orange) unbound, 
(F) monomer B of the heterotetramer (yellow) with monomer A unbound (dark green), (G) 
monomer B (yellow) of the heterotetramer with monomer B unbound (orange).  
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Figure S3: The Sulfotyrosine Binding Site. DBP-RII molecules are in green and yellow. DARC 
molecules are in purple and blue. (A) Phosphate or selenate in the apo DBP-RII structure occupy 
the same position as (B) DARC Y30, defining the sulfotyrosine binding pocket. 
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Figure S4: The DARC binding pockets are distinct from residues previously suggested to bind 
DARC from mutagenesis studies. DBP-RII monomers are in yellow and green. DARC 
monomers are in purple and blue. Residues previously suggested (Singh et al., 2006) to contact 
DARC are in black. 
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Table 1: Data Collection and Refinement Statistics 
 DBP-RII:DARC heterotrimer DBP-RII:DARC heterotetramer 
Data collection   
Space group P2(1) P1 
Cell dimensions   
a, b, c (Å) 59.59, 66.99, 97.92 37.39, 59.47, 91.67 
    α, β, γ ()  90, 102.112, 90 103.143, 91.098, 100.241 
Resolution (Å) 20-1.95 (2.0-1.95) 20-2.6 (2.7-2.6) 
Rsym  .098 (1.01) 0.052 (0.538) 
I / σI 14.54 (2.11) 12.32 (1.69) 
Completeness (%) 99.8 (99.7) 95.2 (93.1) 
Redundancy 7.96 (7.96) 2.4 (2.2) 
   
Refinement   
Resolution (Å) 20-1.95 20-2.6 Å  
No. Reflections 58,872 22,121 
Rwork / Rfree 16.62/20.47 18.29/23.28 
No. Atoms (Non-Hydrogen)    
    Protein 5,422 5,607 
    Ligand Organic 0 12 
    Water 462 52 
B-factors    
    Protein 38.86 70.62 
    Ligand Organic  74.64 
    Water 39.44 52.38 
R.m.s. deviations   
    Bond lengths (Å) 0.005 0.002 
    Bond angles () 0.832 0.543 
*Values in parentheses are for highest-resolution shell. 
Data were collected on a single crystal for each dataset 
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Table 2: Heterotrimer interface residues determined by PDBePISA (Krissinel et al., 2007): all 
residues in the interface are listed sequentially and do not indicate interacting pairs 
 
DARC binding site Dimer Interface 
Primary DARC 
binding interface 
(DARC A to DBP 
1) 
Secondary DARC 
binding interface 
(DARC A to 
DBP2) 
 
DARC 
A 
DBP 1 DARC 
A 
DBP 2 DBP 1 DBP 2 
GLN19 LEU270 PHE22 HIS262 PHE261 ILE265 
LEU20 LYS273 GLU23 ARG263 HIS262 THR266 
ASP21 ARG274 TRP26 ASP264 ASP264 PHE267 
PHE22 ILE277 ASN27 ILE265 LEU270 LEU270 
GLU23 TYR278 TYR30 THR266 TYR271 TYR271 
ASP24 ALA281   ARG274 ARG274 
VAL25 VAL282   LYS275  
TRP26 ASP285   TYR278  
SER28 GLN356     
SER29 THR359     
TYR30 ALA360     
 TYR363     
 SER364     
 LYS366     
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Table 3: Heterotetramer interface residues determined by PDBePISA (Krissinel et al., 2007): all 
residues in the interface are listed sequentially and do not indicate interacting pairs 
 
DARC binding site 1 DARC binding site 2 Dimer Interface 
Primary DARC 
binding interface 
(DARC A to DBP 
1) 
Secondary 
DARC binding 
interace (DARC 
A to DBP 2) 
Primary DARC 
binding interface 
(DARC B to DBP 
1) 
Secondary 
DARC binding 
interface 
(DARC B to DBP 
2) 
 
DARC 
A 
DBP 1 DARC 
A 
DBP 2 DARC 
B 
DBP 1 DARC 
B 
DBP 2 DBP 1 DBP 2 
GLN19 GLU249 GLU23 PHE261 GLN19 LEU270 PHE22 ARG263 HIS262 GLU249 
LEU20 LEU270 TRP26 HIS262 LEU20 LYS273 GLU23 ASP264 ARG263 PHE261 
ASP21 LYS273 ASN27 ARG263 ASP21 ARG274  ILE265 ASP264 GLU249 
PHE22 ARG274 TYR30 ASP264 PHE22 LYS275   ILE265 PHE261 
GLU23 LYS275   GLU23 ILE277   THR266 HIS262 
ASP24 ILE277   ASP24 TYR278   PHE267 ASP264 
VAL25 TYR278   VAL25 ALA281   LEU270 THR266 
TRP26 ALA281   TRP26 VAL282   TYR271 PHE267 
SER28 VAL282   SER28 ASP285   LYS273 LEU270 
SER29 ASP285   SER29 LYS289   ARG274 TYR271 
TYR30 LYS289   TYR30 GLN356   GLU352 ARG274 
 GLN356    THR359   GLN356 LYS275 
 THR359    ALA360    TYR278 
 ALA360    TYR363     
 TYR363    SER364     
 SER364    LYS366     
 LYS366    LYS367     
 LYS367         
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Chapter 5 
 
Conclusions and Future Directions 
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5.1 Introduction 
The hypothesis driving this thesis work is that individual EBL ligands utilize distinct receptor 
binding interfaces and mechanisms to engage their unique receptors on the red blood cell. I 
presented data that supports the presence of unique binding mechanisms for EBL ligands and 
propose that these distinct elements define receptor specificity for individual invasion pathways. 
Examining all members of this family is crucial as the proposed redundancy in function provides 
separate routes for RBC entry, effectively protecting the parasite from immunity and receptor 
polymorphism.  
The work presented here elucidated key binding interface and mechanistic differences 
between two unique EBL members, PfEBA-140 and PvDBP, and allowed for comparison with a 
third characterized family member, PfEBA-175. Initial efforts elucidated the oligomeric state 
and sialic acid binding properties of PfEBA-140, and defined determinants of receptor specificity 
within the P. falciparum EBL family. The work expanded to PvDBP with the goal of identifying 
unique aspects of invasion between the Plasmodium species. Work on PvDBP focused on the 
physical receptor engagement mechanism, and demonstrated a two-step, putatively cooperative 
process for receptor binding. 
The long term objective of this work is to exploit the defined binding elements and 
mechanisms utilized by EBL members in an effort to enhance the immune response to these 
invasion pathways. Current immunization methods utilizing full length RII constructs provide 
the immune system with access to decoy and non-inhibitory epitopes, potentially reducing the 
efficacy of the response. Thus, focusing the immune system on functional binding elements 
identified by crystallographic, biochemical, and mutational studies may limit the elicitation of 
non-inhibitory antibodies and enhance the inhibitory antibody response. The combination of 
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structural, biophysical, and cellular interaction techniques discussed in this work represent an 
experimental system that allows for the delineation of atomic and molecular details defining the 
interface between Plasmodium parasites and their host, and may ultimately aid in developing 
therapeutics and vaccines targeting malaria. Below I discuss the biology and evolution of 
Plasmodium RBC invasion mechanisms, the proposal to specifically target biochemical invasion 
interfaces for vaccine development, and potential future directions.  
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5.2 Receptor engagement mechanisms of the EBL family 
The EBL ligands each bind to unique red blood cell receptors utilizing either a single or dual- 
DBL domain mechanism. This protein architecture differs between P. falciparum and P. vivax. 
Insight into mechanisms and binding elements provided in this work are unique for the most well 
characterized EBL members, including PvDBP, PfEBA-140, and PfEBA-175. Mechanisms and 
binding interfaces for other EBL ligands have not been examined in detail, and thus will not be 
discussed in the context of this thesis research.  
The proposed binding mechanisms for EBL ligands can be separated into three groups based 
on the number of DBL domains in RII and the oligomeric state observed during receptor 
engagement. Proposed mechanisms include: 1) a single DBL domain RII with a dimeric receptor 
interaction; 2) a dual DBL domain RII with a dimeric receptor interaction; and 3) a dual DBL 
domain RII with a monomeric receptor interaction (Figure 1). It is plausible that additional 
biophysical invasion mechanisms exist for the EBL family. 
Understanding the mechanisms of binding for the DBL domain is crucial towards defining 
the full invasion repertoire of the parasite. The presence of the dual DBL domain RII in PfEBA-
175 provides both unique receptor binding interfaces and multimeric interfaces within the DBL 
domain compared with PvDBP, which contains only one DBL domain in RII. However, PfEBA-
175 and PvDBP are mechanistically similar in that they appear to dimerize while binding their 
cellular receptors. In contrast to the multimeric mechanism, all current evidence points to a 
monomeric invasion process for PfEBA-140. This evidence includes SAXS solution studies, 
albeit in the absence of receptor, and the absence of biologically relevant multimeric interfaces in 
the crystal structure. PfEBA-140 also exhibits a distinct sugar binding and receptor binding 
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interface on the DBL domain. In summary, each EBL ligand is characterized by distinct binding 
elements on the conserved DBL domain.  
In addition to distinct biophysical mechanisms, it is highly likely that receptor binding 
interfaces on the DBL domains of uncharacterized EBL ligands and other adhesive proteins in P. 
falciparum are unique. DBL domains of other adhesive proteins, specifically PfEMP1, do in fact 
contain unique binding interfaces on the DBL domain (Higgins, 2008, Khunrae et al., 2009, 
Vigan-Womas et al., 2012). Mechanisms for adhesion of these proteins have not been examined 
in detail, in part due to the complicated, modular nature of the PfEMP1 family, but it is proposed 
that higher order multimers are involved (Kraemer et al., 2006, Batchelor et al., 2011). The DBL 
domain is capable of binding diverse protein receptors, and also interacts with sugar molecules, 
as discussed for the cases of PfEBA-175 and PfEBA-140 (Tolia et al., 2005). It is this plasticity 
of receptor binding interfaces and mechanistic capabilities that makes the DBL domain such 
useful tool for the parasite’s cellular adhesion requirements.  
In addition to oligomeric state, receptor binding by the DBL domains of PfEBA-140 and 
PvDBP induces shifts in physical structure. These shifts likely provide access to the highest 
affinity receptor binding and oligomeric interfaces. PfEBA-140 exhibits a relatively small shift 
of a helix near its sialic acid binding site in the F2 DBL domain, possibly to provide access to the 
protein backbone of GPC. The RBC binding studies presented here suggest that the F2 DBL 
domain is not essential for sugar binding, but instead engages the critical protein backbone of 
GPC. It is plausible that PfEBA-140 will exhibit larger shifts in the presence of full length 
receptor (which includes higher order glycosylation and the protein backbone), and future studies 
may examine these structural shifts and the complete binding interface. The clear next step is to 
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identify the necessary interaction surface on GPC and determine the mechanistic role of 
structural shifts in DBL domains.  
In contrast to the small shift observed for PfEBA-140, the step-wise process of PvDBP 
engaging DARC involves several large shifts in the dimeric interface, which may enhance 
dimerization and thus the avidity of the interaction. PvDBP is similar to PfEBA-140 in that it 
appears that the minimal binding portion of DARC is not the only element of the protein 
involved in binding. The portion identified in this work is the main binding interface; however, 
recent work in the lab suggests that regions outside of this interface may enhance dimerization 
through transient, lower affinity contacts. As the PvDBP:DARC binding interface identified here 
required truncation of the extracellular portion of DARC, accessory contacts could not be 
identified and will require further study to be defined in full.  
In addition to a putative role in driving receptor specificity, invasion ligand multimerization 
is proposed to activate downstream parasite effectors that initiate the merozoite’s downstream 
invasion machinery(Singh et al., 2010). Biological signaling systems often utilize dimerization to 
activate downstream pathways(Klemm et al., 1998).It is plausible that dimerization of the 
extracellular portion of EBL ligands affects the cytoplasmic region, which has no identified 
function but is properly positioned to interact with internal signaling molecules. Examination of 
the interaction between EBL ligands with their receptors demonstrated altered calcium levels in 
merozoites, prompting rhoptry organelle release, supporting a role in signaling(Singh et al., 
2010, Harvey et al., 2012, Weiss et al., 2015). Signaling proteins and a pathway for this 
mechanism have not yet been identified, but are critical in clarifying the molecular network that 
functions during invasion and the specific role of EBL proteins. 
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Multimerization of EBL ligands may play a role in downstream signaling during invasion, 
however, this mechanism cannot explain the role of EBL ligands with proposed monomeric 
receptor interactions such as PfEBA-140. Future work must completely define the oligomeric 
state of PfEBA-140 during engagement of GPC, as previous studies were performed in the 
absence of receptor or only in the presence of sialic acid, a key component of the receptor but not 
the receptor itself. Additionally, it will be valuable to examine the specifics of downstream 
signaling activation during EBL receptor engagement via this monomeric receptor-ligand 
interaction. It is plausible that a unique signaling mechanism is involved for the PfEBA-140 
pathway and other monomeric invasion routes, or that signaling by this pathway is not required 
to complete the invasion process and is prompted by other molecular interactions. 
PfEBA-140 and PvDBP represent two unique members of the EBL family in terms of their 
apparent invasion mechanisms and binding interfaces discussed above. I have proposed that 
novel biochemical interfaces as well as biophysical mechanisms determine receptor specificity 
within this parasite invasion ligand family, and these novelties allow the parasite to utilize 
distinct receptor routes into the RBC. It is unclear why the mechanism of invasion would be 
different between EBL members, and the evolution of these molecular invasion properties has 
not been examined in detail. Furthermore, a proposal describing the origin of multimeric 
assembly for EBL ligands suggests that ligand oligomeric state is at least partially dependent on 
receptor oligomeric state.  In fact, the dimeric nature of PfEBA-175 and PvDBP fit with the 
observed native oligomeric state for their respective receptors (Chasis et al., 1992, Lemmon et 
al., 1992, Treutlein et al., 1992). Additionally, PfEBA-140, appearing to bind as a monomer, fits 
with the proposed monomeric state of its receptor GPC (Chasis et al., 1992). These observations 
fit into a model of human and parasite co-evolution over 100,000 – 180,000 years proposed 
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several years ago and suggest that the parasite has evolved a number of immune evasion 
mechanisms (Mu et al., 2002, Crompton et al., 2014). Future work should examine the 
mechanisms for other EBL ligands and identify the native oligomeric state of corresponding 
receptors. These studies will aid in defining the evolution of unique RBC invasion mechanisms 
and specific biochemical and biophysical determinants of receptor specificity. 
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5.3 Targeting functional elements of DBL domains for vaccination 
A critical aspect of disrupting merozoite entry into the RBC will be direct inhibition of 
functional receptor interaction interfaces and blockage of biophysical invasion elements, such as 
those identified in this work. It is proposed that one mechanism of antibodies targeting highly 
abundant surface proteins on merozoites is opsonization and/or the recruitment of complement 
(Osier et al., 2014, Boyle et al., 2015). These mechanisms contrast the mechanistic and physical 
interaction block demonstrated for invasion ligands expressed only during the invasion process 
(Chen et al., 2013, Wright et al., 2014). Thus, invasion ligands that are exposed at a specific time 
during invasion must be recognized by antibodies and also physically disrupt contact between 
the parasite and the RBC. A focus on targeting functional elements of these invasion proteins is 
necessitated by the presence of decoy epitopes that may focus the B-cell response and diminish 
the production of highly inhibitory antibodies (Godson et al., 1983, Godson et al., 1984, Chen et 
al., 2013). 
Efforts in defining a vaccine that seeks to block RBC invasion have historically proposed 
utilizing multiple antigens to combat parasite immune evasion mechanisms and apparent 
redundancy in invasion pathways (Pandey et al., 2013). Targeting a single invasion ligand is 
thought to be ineffective due to invasion pathway switching or the presence of a population of 
merozoites utilizing a different ligand will overcome the developed immunity. Despite these 
issues, studies in which Aotus monkeys were immunized with recombinant PfEBA-175 RII 
protein or by plasmid DNA were able to demonstrate the induction of immunity to lab strains of 
P. falciparum, which supports the efficacy of the response to EBL proteins (Jones et al., 2001). 
This study was performed with full length RII, thus the immune system had access to variant and 
decoy epitopes, which may have diminished response efficacy. It has been observed that humans 
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in endemic areas do in fact develop a B-cell response to EBL ligands, specifically RII, further 
supporting the role of these proteins in responding to the parasite (Grillot et al., 1990, Ford et al., 
2005, Ford et al., 2007, Ismail et al., 2014). However, these studies do not examine specific 
epitopes or demonstrate a conclusive role in protection, thus it is difficult to conclude what 
function anti-EBL antibodies play in clearing the parasite and challenging to define immune 
evasion mechanisms for invasion proteins. 
The studies presented in this thesis work identified the binding and dimerization interfaces of 
PvDBP as the target of inhibitory antibodies, and illuminated regions outside of the functional 
interfaces as targets of non-inhibitory antibodies. Examination of another merozoite surface 
protein involved during invasion illuminated an immune escape mechanism based on antigenic 
diversity (Dutta et al., 2007). Polymorphism in regions outside of functional interfaces is seen in 
PvDBP as well as other EBL ligands. These observations support an immune escape mechanism 
based on amino acid changes as non-inhibitory antibodies appear to target these polymorphic 
regions. It thus seems evident that conserved mechanistic and binding interfaces represent ideal 
elements for rational immunization strategies.  
Studies examining the T-cell response to a merozoite surface invasion protein demonstrated 
that a subset of cells targeting immunodominant T-cell epitopes are cytolytic while a second 
subset has no cytolytic activity (Hafalla et al., 2013). This result suggests that while a portion of 
targeted epitopes develop a productive response, immunodominant regions can also induce a 
non-inhibitory response. This disparity may also apply to epitopes of the B-cell system, a 
proposal supported by polymorphism in surface adhesins and the identification of decoy epitopes 
in invasion ligands (Dutta et al., 2007, Chen et al., 2013). 
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Based on the identification of the PvDBP receptor binding interface and inhibitory epitopes 
described here, it is expected that the sialic acid binding pockets identified on one face of 
PfEBA-140 RII will be heavily targeted by inhibitory antibodies. In contrast, the opposite face of 
the protein likely serves as a decoy region with immunodominance, similar to the regions outside 
of the dimerization and DARC binding interface of PvDBP. Future studies should examine 
inhibitory and non-inhibitory epitopes to define the overall response to RII. In addition, studies 
should expand into other segments of the EBL proteins. C-terminal extracellular elements of 
EBL ligands may provide greater capacity to dimerize around a receptor or induce downstream 
signaling(Withers-Martinez et al., 2008, Paing et al., 2014). A large portion of the EBL protein 
architecture is uncharacterized in terms of function, and could be examined for both functional 
and antigenic capacity (Wanaguru et al., 2013).It is plausible that large portions of the EBL 
protein presented to the immune system limit the functional response to the EBL invasion 
pathways. In contrast to all other invasion proteins of the EBL and RH families, RH5 is unique 
in that it is the smallest in terms of amino acid length and molecular weight. RH5 seems to 
induce some of the most potent inhibitory antibodies that inhibit numerous lab and wild P. 
falciparum strains, suggesting a strong response to conserved functional elements that is parasite 
strain-transcending. It is plausible that the extended protein architecture of most invasion ligands 
of the EBL and RH families evolved to provide each ligand with a level of immune protection 
that has not yet developed for RH5. Future studies may examine the evolution of the size, shape, 
and overall role of the portions of invasion proteins outside of the minimal receptor binding 
domains of RII for the EBL family and the receptor binding element for the RH family.  
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5.4 EBL ligands in a multi-component vaccine 
Recent studies identified RH5 as a merozoite ligand that is potentially essential to the 
invasion process due to its potent inhibition by antibodies, as discussed above. RH5 is also 
postulated to be a potentially critical contributor to human immunity and thus an essential 
component in a vaccine. However, high antibody titers are typically necessary for productive 
immunity to merozoite ligands, and this is the case for RH5. In fact, even at 10mg/mL of 
polyclonal IgG, in vitro parasite growth inhibition reaches less than 80%, suggesting there are 
still populations of parasites productively invading RBCs(Chen et al., 2014, Wright et al., 2014). 
Immunization with RH5 alone has proven effective in Aotus monkeys; however, these studies 
were small and involve only one re-infection with various parasite lab strains (Douglas et al., 
2015). Trials in large human populations are currently underway and will provide greater insight 
into RH5 function and antigenicity. However, taking into consideration the inability to 
completely eliminate parasite growth in vitro at high antibody concentrations and lack of 
evidence for rapid, long-lasting immunity to RH5, it is critical to identify ideal partners in a 
multi-component vaccine(Williams et al., 2012).  
The key difference between the small studies performed for RH5 and examination of 
protection in endemic areas is the parasite’s tremendous genetic diversity and the prospect of 
consistent re-infection. Focusing on a single invasion ligand for immunity thus provides the 
parasite with a quick genetic escape from the vaccine. A study of a less virulent Plasmodium 
species in a mouse model of infection demonstrated the evolution of more virulent parasites due 
to immunization with a single merozoite invasion ligand, supporting the necessity of a multi-
component vaccine (Barclay et al., 2012). Furthermore, the polymorphic nature of most invasion 
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ligands and the identification of numerous non-inhibitory antibodies suggest that part of the 
merozoite’s immune evasion mechanism involves diminishing the productive response.  
Similar to antibody epitopes identified for PvDBP and PfEBA-175, mapping of RH5 
inhibitory epitopes illuminated functional interfaces as targeted regions, likely causing a block in 
the mechanism of binding. Studies examining the epitopes of non-inhibitory antibodies are not 
readily available, although it was demonstrated that non-inhibitory antibodies do not bind to 
RH5, suggesting that a subset of induced antibodies are ineffective and do not even maintain the 
ability to bind the antigen(Wright et al., 2014). This result supports the presence of a parasite 
immune evasion mechanism that provides the B-cell system with access to immunodominant but 
non-inhibitory epitopes, effectively limiting productive inhibition.  
In addition to the functional interfaces of adhesions assessed in this study, other RBC 
invasion ligands and blood-stage adhesion proteins containing the DBL domain are being 
targeted and demonstrate the value of identifying specific functional elements for immunization. 
In the case of PfEMP1 CIDR domains,a highly alpha helical domain that functions similarly to 
the DBL domain, conserved structural elements allow the parasite to increase the level of 
polymorphism without losing receptor binding function(Lau et al., 2015).Perhaps a common 
thread exists in terms of antigenic potential of the DBL domain. If a common structural or 
sequence theme among non-inhibitory, immunodominant elements were identified, it would 
open avenues to understand the complete immune evasion mechanisms of the parasite and allow 
for rational design of epitopes that may generate greater specificity in the B-cell response.  
The thesis research presented here identified specific regions of proteins for targeted 
immunization in a multi-component vaccine that disrupts RBC invasion, focusing specifically on 
the DBL domain. Epitopes can be targeted in several ways, specifically by mutating immune-
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dominant non-inhibitory epitopes and by shrouding non-inhibitory epitopes with glycosylation 
(Ntumngia et al., 2012, Sampath et al., 2013). Similar approaches effectively exploited broadly-
neutralizing epitopes to viral antigens, supporting the efficacy of these techniques(Corti et al., 
2013). It has been established that antibodies are crucial during the response to the parasite, as 
demonstrated by the alleviation of disease through transfer of purified IgG from immune 
individuals to those with active malaria infection (Cohen et al., 1961).However, it is still not 
clear what proteins are the most effective targets or what antibody mechanisms provide the 
greatest and longest lasting levels of protection. Repeated infection is proposed to elicit 
protective antibodies targeting PfEMP1, supporting the efficacy of the immune response to 
surface exposed adhesins containing the DBL fold (Bull et al., 1998).The question still remains 
as to how to best formulate a vaccine and how to present the antigen(s) to the human immune 
system. The work presented here advances our understanding of the Plasmodium DBL domain 
and provides a greater capability to target specific functional and structural elements of two EBL 
invasion ligands for rational vaccination efforts.  
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5.5 Figures 
 
Figure 1. Summary of proposed invasion mechanisms for Plasmodium EBL family members. 
PfEBA-140 (left) utilizes the dual-DBL domain monomeric engagement mechanism. PvDBP 
(middle) engages its receptor in a two-step mechanism using a single DBL domain to form 
dimer. PfEBA-175 (right) also dimerizes around its receptor, but does so with a dual DBL 
domain RII.   
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